original_id,original_type,normalized_id,normalized_type,PubMedID
trastuzumab deruxtecan,drug,trastuzumab deruxtecan,drug,39491462
metastatic breast cancer,disease,metastatic breast cancer,disease,39491462
patients,class_id,patients,class_id,39491462
her2 amplification,semantic_types,her2 amplification,semantic_types,39491462
antibody drug conjugates,drug,antibody drug conjugates,drug,39491462
renal toxicity,adverse event,renal toxicity,adverse event,39488644
hematological toxicity,adverse event,hematological toxicity,adverse event,39488644
peptide receptor radionuclide therapy (PRRT),treatment,peptide receptor radionuclide therapy (PRRT),treatment,39488644
neuroendocrine tumor (NET) patients,patient group,neuroendocrine tumor (NET) patients,patient group,39488644
renal function,physiological function,renal function,physiological function,39488644
hematological function,physiological function,hematological function,physiological function,39488644
177Lu dotatate,drug,177Lu dotatate,drug,39488644
90Y dotatoc,drug,90Y dotatoc,drug,39488644
white blood cell counts (WBC),physiological measurement,white blood cell counts (WBC),physiological measurement,39488644
platelet counts,physiological measurement,platelet counts,physiological measurement,39488644
hemoglobin levels,physiological measurement,hemoglobin levels,physiological measurement,39488644
overall survival (OS),clinical outcome,overall survival (OS),clinical outcome,39488644
progression free survival (PFS),clinical outcome,progression free survival (PFS),clinical outcome,39488644
vinpocetine,drug,vinpocetine,drug,39480853
hepatocellular carcinoma,disease,hepatocellular carcinoma,disease,39480853
rats,organism,rats,organism,39480853
diethylnitrosamine,drug,diethylnitrosamine,drug,39480853
livers,anatomical structure,livers,anatomical structure,39480853
ccnd1,protein,ccnd1,protein,39480853
ki 67,protein,ki 67,protein,39480853
bcl-2,protein,bcl-2,protein,39480853
bax,protein,bax,protein,39480853
cleaved caspase 3,protein,cleaved caspase 3,protein,39480853
nf-kb,protein,nf-kb,protein,39480853
stat3,protein,stat3,protein,39480853
hif-1,protein,hif-1,protein,39480853
icam-1,protein,icam-1,protein,39480853
tgf-1,protein,tgf-1,protein,39480853
nab sirolimus,preferred_label,nab sirolimus,preferred_label,39487711
temozolomide,preferred_label,temozolomide,preferred_label,39487711
irinotecan,preferred_label,irinotecan,preferred_label,39487711
thrombocytopenia,preferred_label,thrombocytopenia,preferred_label,39487711
Ewing sarcoma,preferred_label,Ewing sarcoma,preferred_label,39487711
skin cancer,disease,skin cancer,disease,39485529
melanoma,disease,melanoma,disease,39485529
BRAF inhibitors,drug,BRAF inhibitors,drug,39485529
vemurafenib,drug,vemurafenib,drug,39485529
dabrafenib,drug,dabrafenib,drug,39485529
MEK inhibitors,drug,MEK inhibitors,drug,39485529
trametinib,drug,trametinib,drug,39485529
cobimetinib,drug,cobimetinib,drug,39485529
immune checkpoint inhibitors,drug,immune checkpoint inhibitors,drug,39485529
ipilimumab,drug,ipilimumab,drug,39485529
onco nephrology,preferred_label,onco nephrology,preferred_label,39482406
renal events,preferred_label,renal events,preferred_label,39482406
cancer patients,preferred_label,cancer patients,preferred_label,39482406
renal toxicity,preferred_label,renal toxicity,preferred_label,39482406
kidney protective measures,preferred_label,kidney protective measures,preferred_label,39482406
adult patients,preferred_label,adult patients,preferred_label,39482406
anti tumor treatments,preferred_label,anti tumor treatments,preferred_label,39482406
questionnaire,preferred_label,questionnaire,preferred_label,39482406
solid tumor,preferred_label,solid tumor,preferred_label,39482406
renal adverse events,preferred_label,renal adverse events,preferred_label,39482406
anticancer treatment,preferred_label,anticancer treatment,preferred_label,39482406
hydration,preferred_label,hydration,preferred_label,39482406
nausea vomiting,preferred_label,nausea vomiting,preferred_label,39482406
alkaline water,preferred_label,alkaline water,preferred_label,39482406
dehydration,preferred_label,dehydration,preferred_label,39482406
information,preferred_label,information,preferred_label,39482406
online resources,preferred_label,online resources,preferred_label,39482406
patients,preferred_label,patients,preferred_label,39482406
educational sheets,preferred_label,educational sheets,preferred_label,39482406
trastuzumab,drug,trastuzumab,drug,39478296
corneal ulceration,disease,corneal ulceration,disease,39478296
breast cancer,disease,breast cancer,disease,39478296
metastatic breast cancer,disease,metastatic breast cancer,disease,39478296
corneal ulcer,disease,corneal ulcer,disease,39478296
keratoplasty,procedure,keratoplasty,procedure,39478296
ocular surface therapy,procedure,ocular surface therapy,procedure,39478296
patient,person,patient,person,39478296
eye infection,disease,eye infection,disease,39478296
optometrist,profession,optometrist,profession,39478296
inavolisib,drug,inavolisib,drug,39476340
pik3ca,gene,pik3ca,gene,39476340
palbociclib,drug,palbociclib,drug,39476340
fulvestrant,drug,fulvestrant,drug,39476340
breast cancer,disease,breast cancer,disease,39476340
neutropenia,adverse event,neutropenia,adverse event,39476340
hyperglycemia,adverse event,hyperglycemia,adverse event,39476340
stomatitis,adverse event,stomatitis,adverse event,39476340
diarrhea,adverse event,diarrhea,adverse event,39476340
gefitinib,drug,gefitinib,drug,39472861
chemotherapy,treatment,chemotherapy,treatment,39472861
bevacizumab,drug,bevacizumab,drug,39472861
epidermal growth factor receptor (EGFR),gene,epidermal growth factor receptor (EGFR),gene,39472861
pemetrexed,drug,pemetrexed,drug,39472861
carboplatin,drug,carboplatin,drug,39472861
non squamous non small cell lung cancer (NSCLC),disease,non squamous non small cell lung cancer (NSCLC),disease,39472861
neutropenia,adverse event,neutropenia,adverse event,39472861
thrombocytopenia,adverse event,thrombocytopenia,adverse event,39472861
nausea,adverse event,nausea,adverse event,39472861
skin rash,adverse event,skin rash,adverse event,39472861
bleeding,adverse event,bleeding,adverse event,39472861
increased ALT,adverse event,increased ALT,adverse event,39472861
combination therapy,treatment,combination therapy,treatment,39472861
afatinib,drug,afatinib,drug,39471023
non small cell lung cancer,disease,non small cell lung cancer,disease,39471023
epidermal growth factor receptor,protein,epidermal growth factor receptor,protein,39471023
egfr mutations,genetic mutation,egfr mutations,genetic mutation,39471023
elderly patients,patient demographic,elderly patients,patient demographic,39471023
physical condition,clinical characteristic,physical condition,clinical characteristic,39471023
comorbidities,medical condition,comorbidities,medical condition,39471023
initial dosage,treatment parameter,initial dosage,treatment parameter,39471023
dose adjustments,treatment parameter,dose adjustments,treatment parameter,39471023
retrospective analysis,study design,retrospective analysis,study design,39471023
cancer centers,medical facility,cancer centers,medical facility,39471023
brain metastases,medical condition,brain metastases,medical condition,39471023
toxicities,adverse effect,toxicities,adverse effect,39471023
Vietnam,geographical location,Vietnam,geographical location,39471023
neoadjuvant chemotherapy,may_treat,neoadjuvant chemotherapy,may_treat,39468597
ovarian cancer,has disease,ovarian cancer,has disease,39468597
nanoparticle albumin bound paclitaxel,may_treat,nanoparticle albumin bound paclitaxel,may_treat,39468597
carboplatin,may_treat,carboplatin,may_treat,39468597
unresectable ovarian cancer,has disease,unresectable ovarian cancer,has disease,39468597
neutropenia,adverse event occurs in,neutropenia,adverse event occurs in,39468597
alopecia,adverse event occurs in,alopecia,adverse event occurs in,39468597
nivolumab,drug,nivolumab,drug,39468513
chemotherapy,drug,chemotherapy,drug,39468513
gastric cancer,disease,gastric cancer,disease,39468513
her2,gene,her2,gene,39468513
programmed cell death ligand 1,protein,programmed cell death ligand 1,protein,39468513
neutropenia,adverse event,neutropenia,adverse event,39468513
thrombocytopenia,adverse event,thrombocytopenia,adverse event,39468513
diarrhea,adverse event,diarrhea,adverse event,39468513
anemia,adverse event,anemia,adverse event,39468513
head and neck squamous cell carcinoma,class_id,head and neck squamous cell carcinoma,class_id,39467871
cisplatin based chemoradiotherapy,class_id,cisplatin based chemoradiotherapy,class_id,39467871
toxicities,preferred_label,toxicities,preferred_label,39467871
patients,preferred_label,patients,preferred_label,39467871
low skeletal muscle mass,preferred_label,low skeletal muscle mass,preferred_label,39467871
experiences,preferred_label,experiences,preferred_label,39467871
qualitative study,preferred_label,qualitative study,preferred_label,39467871
interviews,preferred_label,interviews,preferred_label,39467871
topic guide,preferred_label,topic guide,preferred_label,39467871
thematic analysis,preferred_label,thematic analysis,preferred_label,39467871
supporting network,preferred_label,supporting network,preferred_label,39467871
counseling,preferred_label,counseling,preferred_label,39467871
excessive dna damage,preferred_label,excessive dna damage,preferred_label,39465258
pcd,preferred_label,pcd,preferred_label,39465258
panoptosis,preferred_label,panoptosis,preferred_label,39465258
pyroptosis,preferred_label,pyroptosis,preferred_label,39465258
apoptosis,preferred_label,apoptosis,preferred_label,39465258
necroptosis,preferred_label,necroptosis,preferred_label,39465258
zbp1,preferred_label,zbp1,preferred_label,39465258
endogenous retroviruses,preferred_label,endogenous retroviruses,preferred_label,39465258
ervs,preferred_label,ervs,preferred_label,39465258
chemotherapeutic drugs,preferred_label,chemotherapeutic drugs,preferred_label,39465258
tumor tissue,preferred_label,tumor tissue,preferred_label,39465258
colorectal cancer patients,preferred_label,colorectal cancer patients,preferred_label,39465258
dsrna,preferred_label,dsrna,preferred_label,39465258
chemotherapy,preferred_label,chemotherapy,preferred_label,39465258
normal tissues,preferred_label,normal tissues,preferred_label,39465258
tumor immunotherapy,preferred_label,tumor immunotherapy,preferred_label,39456702
cancer treatment,preferred_label,cancer treatment,preferred_label,39456702
immune cells,preferred_label,immune cells,preferred_label,39456702
tumor microenvironment,preferred_label,tumor microenvironment,preferred_label,39456702
effector immune cells,preferred_label,effector immune cells,preferred_label,39456702
toxic side effects,preferred_label,toxic side effects,preferred_label,39456702
inflammatory factor storm,preferred_label,inflammatory factor storm,preferred_label,39456702
immune related adverse events (IRAEs),preferred_label,immune related adverse events (IRAEs),preferred_label,39456702
intestinal epithelial barrier permeability,preferred_label,intestinal epithelial barrier permeability,preferred_label,39456702
inflammatory bowel disease (IBD),preferred_label,inflammatory bowel disease (IBD),preferred_label,39456702
TNF,preferred_label,TNF,preferred_label,39456702
IFN,preferred_label,IFN,preferred_label,39456702
combo immune checkpoint inhibitors induced colitis,preferred_label,combo immune checkpoint inhibitors induced colitis,preferred_label,39456702
epithelial cells,preferred_label,epithelial cells,preferred_label,39456702
breast cancer,class_id,breast cancer,class_id,39453820
chemotherapy,class_id,chemotherapy,class_id,39453820
surgical intervention,class_id,surgical intervention,class_id,39453820
radiation therapy,class_id,radiation therapy,class_id,39453820
hormone therapy,class_id,hormone therapy,class_id,39453820
biological therapy,class_id,biological therapy,class_id,39453820
plants,class_id,plants,class_id,39453820
anticancer drugs,class_id,anticancer drugs,class_id,39453820
immune checkpoint inhibitors,preferred_label,immune checkpoint inhibitors,preferred_label,39450164
immune related adverse events,preferred_label,immune related adverse events,preferred_label,39450164
endocrine toxicities,preferred_label,endocrine toxicities,preferred_label,39450164
diabetes mellitus,preferred_label,diabetes mellitus,preferred_label,39450164
thyroid dysfunction,preferred_label,thyroid dysfunction,preferred_label,39450164
diabetic ketoacidosis,preferred_label,diabetic ketoacidosis,preferred_label,39450164
hypothyroidism,preferred_label,hypothyroidism,preferred_label,39450164
cervical carcinoma,preferred_label,cervical carcinoma,preferred_label,39450164
insulin treatment,preferred_label,insulin treatment,preferred_label,39450164
chemotherapy,preferred_label,chemotherapy,preferred_label,39450164
spartalizumab,preferred_label,spartalizumab,preferred_label,39448966
platinum doublet chemotherapy,semantic_types,platinum doublet chemotherapy,semantic_types,39448966
canakinumab,preferred_label,canakinumab,preferred_label,39448966
non small cell lung cancer,semantic_types,non small cell lung cancer,semantic_types,39448966
gemcitabine,preferred_label,gemcitabine,preferred_label,39448966
cisplatin,preferred_label,cisplatin,preferred_label,39448966
pemetrexed,preferred_label,pemetrexed,preferred_label,39448966
paclitaxel,preferred_label,paclitaxel,preferred_label,39448966
carboplatin,preferred_label,carboplatin,preferred_label,39448966
neutropenic colitis,semantic_types,neutropenic colitis,semantic_types,39448966
posterior reversible encephalopathy syndrome,semantic_types,posterior reversible encephalopathy syndrome,semantic_types,39448966
hyponatremia,semantic_types,hyponatremia,semantic_types,39448966
clinicaltrials.gov,source,clinicaltrials.gov,source,39448966
triple negative breast carcinoma,class_id,triple negative breast carcinoma,class_id,39446014
chemotherapy,preferred_label,chemotherapy,preferred_label,39446014
monoclonal antibody drug conjugate sacituzumab govitecan,preferred_label,monoclonal antibody drug conjugate sacituzumab govitecan,preferred_label,39446014
elderly patient,preferred_label,elderly patient,preferred_label,39446014
triple negative breast carcinoma,class_id,triple negative breast carcinoma,class_id,39446012
sacituzumab govitecan,class_id,sacituzumab govitecan,class_id,39446012
elderly patients,class_id,elderly patients,class_id,39446012
metastatic breast cancer,class_id,metastatic breast cancer,class_id,39446012
luminal b,class_id,luminal b,class_id,39446012
hormonal,class_id,hormonal,class_id,39446012
chemotherapeutic treatment,class_id,chemotherapeutic treatment,class_id,39446012
diarrhea,class_id,diarrhea,class_id,39446012
quality of life,class_id,quality of life,class_id,39446012
inflammatory factors,semantic_types,inflammatory factors,semantic_types,39445010
coronavirus disease 19,semantic_types,coronavirus disease 19,semantic_types,39445010
covid 19,semantic_types,covid 19,semantic_types,39445010
acute respiratory syndrome coronavirus 2,semantic_types,acute respiratory syndrome coronavirus 2,semantic_types,39445010
sars cov 2,semantic_types,sars cov 2,semantic_types,39445010
imatinib,preferred_label,imatinib,preferred_label,39445010
norimatinib,preferred_label,norimatinib,preferred_label,39445010
gastrointestinal stromal tumor,semantic_types,gastrointestinal stromal tumor,semantic_types,39445010
tdm,preferred_label,tdm,preferred_label,39445010
pharmacogenetic,preferred_label,pharmacogenetic,preferred_label,39445010
polymorphisms,semantic_types,polymorphisms,semantic_types,39445010
genes,semantic_types,genes,semantic_types,39445010
cyp3a4,preferred_label,cyp3a4,preferred_label,39445010
cyp3a5,preferred_label,cyp3a5,preferred_label,39445010
abcg2,preferred_label,abcg2,preferred_label,39445010
sars cov 2 infection,semantic_types,sars cov 2 infection,semantic_types,39445010
side effects,semantic_types,side effects,semantic_types,39445010
acute myeloid leukemia,class_id,acute myeloid leukemia,class_id,39443599
stem cell,class_id,stem cell,class_id,39443599
hematopoietic system,class_id,hematopoietic system,class_id,39443599
chemotherapy,class_id,chemotherapy,class_id,39443599
cytarabine,class_id,cytarabine,class_id,39443599
daunorubicin,class_id,daunorubicin,class_id,39443599
therapy protocol,class_id,therapy protocol,class_id,39443599
blood cells,class_id,blood cells,class_id,39443599
adverse effects,class_id,adverse effects,class_id,39443599
stem cell niches,class_id,stem cell niches,class_id,39443599
mathematical model,class_id,mathematical model,class_id,39443599
clinical trial data,class_id,clinical trial data,class_id,39443599
cd34 cd38 aldh cells,class_id,cd34 cd38 aldh cells,class_id,39443599
complete remission,class_id,complete remission,class_id,39443599
g csf priming,class_id,g csf priming,class_id,39443599
salvage therapy,class_id,salvage therapy,class_id,39443599
minimal residual disease markers,class_id,minimal residual disease markers,class_id,39443599
immune check inhibitors,class_id,immune check inhibitors,class_id,39443053
biologic therapy,class_id,biologic therapy,class_id,39443053
cancer cells,class_id,cancer cells,class_id,39443053
toxicities,class_id,toxicities,class_id,39443053
immune related adverse events,class_id,immune related adverse events,class_id,39443053
endocrinopathies,class_id,endocrinopathies,class_id,39443053
organ system,class_id,organ system,class_id,39443053
preoperative assessment,class_id,preoperative assessment,class_id,39443053
liver cancer,disease,liver cancer,disease,39435040
low intensity ultrasound,treatment,low intensity ultrasound,treatment,39435040
nanomedicine delivery systems,drug delivery system,nanomedicine delivery systems,drug delivery system,39435040
folic acid modified nanoparticles,drug delivery system,folic acid modified nanoparticles,drug delivery system,39435040
fluorescent dye dir,chemical compound,fluorescent dye dir,chemical compound,39435040
liquid fluorocarbon pfp,chemical compound,liquid fluorocarbon pfp,chemical compound,39435040
crebanine polyethylene glycol polylactic acid copolymer nanoparticles,drug delivery system,crebanine polyethylene glycol polylactic acid copolymer nanoparticles,drug delivery system,39435040
H22 cells of mouse hepatoma,cell line,H22 cells of mouse hepatoma,cell line,39435040
small animal in vivo imaging system,imaging system,small animal in vivo imaging system,imaging system,39435040
hepatocellular carcinoma transplantation model,animal model,hepatocellular carcinoma transplantation model,animal model,39435040
liver,organ,liver,organ,39435040
kidney,organ,kidney,organ,39435040
sj gren s syndrome,preferred_label,sj gren s syndrome,preferred_label,39434886
immune checkpoint inhibitors,preferred_label,immune checkpoint inhibitors,preferred_label,39434886
autoimmune disease,semantic_types,autoimmune disease,semantic_types,39434886
breast cancer metastasis,preferred_label,breast cancer metastasis,preferred_label,39434886
atezolizumab,preferred_label,atezolizumab,preferred_label,39434886
nab paclitaxel,preferred_label,nab paclitaxel,preferred_label,39434886
prednisone,preferred_label,prednisone,preferred_label,39434886
pilocarpine,preferred_label,pilocarpine,preferred_label,39434886
hydroxychloroquine,preferred_label,hydroxychloroquine,preferred_label,39434886
neoadjuvant chemotherapy,preferred_label,neoadjuvant chemotherapy,preferred_label,39434886
surgery,preferred_label,surgery,preferred_label,39434886
radiotherapy,preferred_label,radiotherapy,preferred_label,39434886
lung nodules,preferred_label,lung nodules,preferred_label,39434886
lymph node involvement,preferred_label,lymph node involvement,preferred_label,39434886
multidisciplinary collaboration,preferred_label,multidisciplinary collaboration,preferred_label,39434886
cancer control,preferred_label,cancer control,preferred_label,39434886
patient quality of life,preferred_label,patient quality of life,preferred_label,39434886
rheumatological iraes,preferred_label,rheumatological iraes,preferred_label,39434886
cancer immunotherapy,preferred_label,cancer immunotherapy,preferred_label,39434886
immune checkpoint inhibitors,preferred_label,immune checkpoint inhibitors,preferred_label,39433998
chemotherapy,preferred_label,chemotherapy,preferred_label,39433998
endometrial cancer,preferred_label,endometrial cancer,preferred_label,39433998
network meta analysis,preferred_label,network meta analysis,preferred_label,39433998
patients,preferred_label,patients,preferred_label,39433998
phase i trials,class_id,phase i trials,class_id,39432880
oncology drug combinations,class_id,oncology drug combinations,class_id,39432880
toxicity adaptive lists design,class_id,toxicity adaptive lists design,class_id,39432880
tale,preferred_label,tale,preferred_label,39432880
dose escalation,class_id,dose escalation,class_id,39432880
de-escalation,synonyms,de-escalation,synonyms,39432880
dose levels,class_id,dose levels,class_id,39432880
toxicities,class_id,toxicities,class_id,39432880
maximum tolerated dose (MTD),preferred_label,maximum tolerated dose (MTD),preferred_label,39432880
bayesian optimal interval design,preferred_label,bayesian optimal interval design,preferred_label,39432880
copula,preferred_label,copula,preferred_label,39432880
product of independent beta probabilities escalation,class_id,product of independent beta probabilities escalation,class_id,39432880
continual reassessment method for partial ordering designs,class_id,continual reassessment method for partial ordering designs,class_id,39432880
overdosing patients,class_id,overdosing patients,class_id,39432880
patient safety,class_id,patient safety,class_id,39432880
r shiny application,preferred_label,r shiny application,preferred_label,39432880
r package,preferred_label,r package,preferred_label,39432880
operating characteristics,class_id,operating characteristics,class_id,39432880
risk of assigning highly toxic dose combinations,class_id,risk of assigning highly toxic dose combinations,class_id,39432880
mammary gland carcinoma,class_id,mammary gland carcinoma,class_id,39425456
hypoxia inducible factor 1alpha,preferred_label,hypoxia inducible factor 1alpha,preferred_label,39425456
fih 1,preferred_label,fih 1,preferred_label,39425456
chemical compounds,class_id,chemical compounds,class_id,39425456
bbap 8,preferred_label,bbap 8,preferred_label,39425456
mcf 7 cells,class_id,mcf 7 cells,class_id,39425456
7 12 dimethylbenz a anthracene,preferred_label,7 12 dimethylbenz a anthracene,preferred_label,39425456
Wistar rats,preferred_label,Wistar rats,preferred_label,39425456
glut 1,preferred_label,glut 1,preferred_label,39425456
vegf,preferred_label,vegf,preferred_label,39425456
twist 1,preferred_label,twist 1,preferred_label,39425456
bcl 2,preferred_label,bcl 2,preferred_label,39425456
bax,preferred_label,bax,preferred_label,39425456
caspase 8,preferred_label,caspase 8,preferred_label,39425456
caspase 3,preferred_label,caspase 3,preferred_label,39425456
pyrotinib,drug,pyrotinib,drug,39425028
metronomic oral etoposide,drug,metronomic oral etoposide,drug,39425028
her2 positive metastatic breast cancer,disease,her2 positive metastatic breast cancer,disease,39425028
trastuzumab,drug,trastuzumab,drug,39425028
nausea,adverse event,nausea,adverse event,39425028
vomiting,adverse event,vomiting,adverse event,39425028
diarrhea,adverse event,diarrhea,adverse event,39425028
anemia,adverse event,anemia,adverse event,39425028
peripheral neuropathy,adverse event,peripheral neuropathy,adverse event,39425028
cisplatin,drug,cisplatin,drug,39423903
nephrotoxicity,adverse event,nephrotoxicity,adverse event,39423903
ototoxicity,adverse event,ototoxicity,adverse event,39423903
neurotoxicity,adverse event,neurotoxicity,adverse event,39423903
myelosuppression,adverse event,myelosuppression,adverse event,39423903
oxidative stress,biological process,oxidative stress,biological process,39423903
inflammation,biological process,inflammation,biological process,39423903
dna damage,biological process,dna damage,biological process,39423903
cellular apoptosis,biological process,cellular apoptosis,biological process,39423903
kidney disease,disease,kidney disease,disease,39423903
hearing impairment,condition,hearing impairment,condition,39423903
neuropathy,condition,neuropathy,condition,39423903
impaired liver function,condition,impaired liver function,condition,39423903
comorbidities,condition,comorbidities,condition,39423903
therapeutic strategies,intervention,therapeutic strategies,intervention,39423903
patient outcomes,outcome,patient outcomes,outcome,39423903
cancer care,care setting,cancer care,care setting,39423903
Chemotherapy,may_treat,Chemotherapy,may_treat,39418176
Platinum drugs,drug associated with AE,Platinum drugs,drug associated with AE,39418176
Hollow copper sulfide nanocubes,class_id,Hollow copper sulfide nanocubes,class_id,39418176
Pt IV drugs,drug associated with AE,Pt IV drugs,drug associated with AE,39418176
Glutathione,may_prevent,Glutathione,may_prevent,39418176
Reactive oxygen species,produces,Reactive oxygen species,produces,39418176
large b cell lymphomas,class_id,large b cell lymphomas,class_id,39415456
anti cd19 chimeric antigen receptor,class_id,anti cd19 chimeric antigen receptor,class_id,39415456
Tisagenlecleucel,preferred_label,Tisagenlecleucel,preferred_label,39415456
Axicabtagene ciloleucel,preferred_label,Axicabtagene ciloleucel,preferred_label,39415456
University Hospitals Leuven,class_id,University Hospitals Leuven,class_id,39415456
cytokine release syndrome,preferred_label,cytokine release syndrome,preferred_label,39415456
immune effector cell associated neurotoxicity syndrome,preferred_label,immune effector cell associated neurotoxicity syndrome,preferred_label,39415456
cyclophosphamide,drug,cyclophosphamide,drug,39414093
arabinogalactan,polymer,arabinogalactan,polymer,39414093
aptamers,oligonucleotide ligands,aptamers,oligonucleotide ligands,39414093
erlich ascites cells,cell line,erlich ascites cells,cell line,39414093
ehrlich carcinoma,tumor model,ehrlich carcinoma,tumor model,39414093
tumor bearing mice,animal model,tumor bearing mice,animal model,39414093
cisplatin,drug,cisplatin,drug,39413735
nasopharyngeal carcinoma,disease,nasopharyngeal carcinoma,disease,39413735
gemcitabine,drug,gemcitabine,drug,39413735
toripalimab,drug,toripalimab,drug,39413735
patients,patient cohort,patients,patient cohort,39413735
adverse events,adverse event,adverse events,adverse event,39413735
headache,adverse event,headache,adverse event,39413735
nausea,adverse event,nausea,adverse event,39413735
brentuximab vedotin,drug,brentuximab vedotin,drug,39413375
classic hodgkin's lymphoma,disease,classic hodgkin's lymphoma,disease,39413375
adult patients,patient,adult patients,patient,39413375
pediatric patients,patient,pediatric patients,patient,39413375
radiation therapy,treatment,radiation therapy,treatment,39413375
nivolumab,drug,nivolumab,drug,39413375
doxorubicin,drug,doxorubicin,drug,39413375
vinblastine,drug,vinblastine,drug,39413375
dacarbazine,drug,dacarbazine,drug,39413375
Chemotherapy,may_treat,Chemotherapy,may_treat,39413318
Radiation therapy,may_treat,Radiation therapy,may_treat,39413318
Cutaneous adverse events,drug AE occurs in,Cutaneous adverse events,drug AE occurs in,39413318
Toxic erythema of chemotherapy,drug AE occurs in,Toxic erythema of chemotherapy,drug AE occurs in,39413318
Radiation-induced dermatitis,drug AE occurs in,Radiation-induced dermatitis,drug AE occurs in,39413318
Vitamin D supplementation,may_treat,Vitamin D supplementation,may_treat,39413318
Breast cancer,has disease,Breast cancer,has disease,39413318
Colorectal cancer,has disease,Colorectal cancer,has disease,39413318
Probiotics,preferred_label,Probiotics,preferred_label,39410854
Chemotherapy-induced diarrhea,preferred_label,Chemotherapy-induced diarrhea,preferred_label,39410854
Cancer patients,preferred_label,Cancer patients,preferred_label,39410854
Osmotic diarrhea,preferred_label,Osmotic diarrhea,preferred_label,39410854
Colonic crypts,preferred_label,Colonic crypts,preferred_label,39410854
Villi,preferred_label,Villi,preferred_label,39410854
Radiotherapy,preferred_label,Radiotherapy,preferred_label,39410854
Chemotherapy agents,preferred_label,Chemotherapy agents,preferred_label,39410854
Chloride absorption,preferred_label,Chloride absorption,preferred_label,39410854
Water release,preferred_label,Water release,preferred_label,39410854
Inflammatory pathways,preferred_label,Inflammatory pathways,preferred_label,39410854
Immunological responses,preferred_label,Immunological responses,preferred_label,39410854
Angiogenesis responses,preferred_label,Angiogenesis responses,preferred_label,39410854
Digestive enzymes metabolism,preferred_label,Digestive enzymes metabolism,preferred_label,39410854
Gut microbiota,preferred_label,Gut microbiota,preferred_label,39410854
Clinical research,preferred_label,Clinical research,preferred_label,39410854
Strain combinations,preferred_label,Strain combinations,preferred_label,39410854
Dosages,preferred_label,Dosages,preferred_label,39410854
immune checkpoint inhibitors,preferred_label,immune checkpoint inhibitors,preferred_label,39405648
immune related adverse events,preferred_label,immune related adverse events,preferred_label,39405648
adjuvant setting,preferred_label,adjuvant setting,preferred_label,39405648
real world data,preferred_label,real world data,preferred_label,39405648
patient population,preferred_label,patient population,preferred_label,39405648
clinical trial data,preferred_label,clinical trial data,preferred_label,39405648
anti pd1 therapy,preferred_label,anti pd1 therapy,preferred_label,39405648
nivolumab,preferred_label,nivolumab,preferred_label,39405648
resected stage iii iv melanoma,preferred_label,resected stage iii iv melanoma,preferred_label,39405648
national databases,preferred_label,national databases,preferred_label,39405648
immunotox database,preferred_label,immunotox database,preferred_label,39405648
danish metastatic melanoma database,preferred_label,danish metastatic melanoma database,preferred_label,39405648
organ systems,preferred_label,organ systems,preferred_label,39405648
toxicities,preferred_label,toxicities,preferred_label,39405648
progression free survival,preferred_label,progression free survival,preferred_label,39405648
overall survival,preferred_label,overall survival,preferred_label,39405648
melanoma relapse,preferred_label,melanoma relapse,preferred_label,39405648
gender,preferred_label,gender,preferred_label,39405648
age,preferred_label,age,preferred_label,39405648
seasonal variation,preferred_label,seasonal variation,preferred_label,39405648
Cytokines,preferred_label,Cytokines,preferred_label,39403930
Immune checkpoint inhibition,preferred_label,Immune checkpoint inhibition,preferred_label,39403930
T helper cell pathways,preferred_label,T helper cell pathways,preferred_label,39403930
Solid tumors,preferred_label,Solid tumors,preferred_label,39403930
Autoimmune disorders,preferred_label,Autoimmune disorders,preferred_label,39403930
IL-5,preferred_label,IL-5,preferred_label,39403930
IL-6,preferred_label,IL-6,preferred_label,39403930
IL-17F,preferred_label,IL-17F,preferred_label,39403930
TNF,preferred_label,TNF,preferred_label,39403930
Objective response rate,preferred_label,Objective response rate,preferred_label,39403930
Cancer-specific mortality,preferred_label,Cancer-specific mortality,preferred_label,39403930
All-cause mortality,preferred_label,All-cause mortality,preferred_label,39403930
IL-6 blockade,preferred_label,IL-6 blockade,preferred_label,39403930
Neoadjuvant endocrine therapy,preferred_label,Neoadjuvant endocrine therapy,preferred_label,39384801
Breast cancer,preferred_label,Breast cancer,preferred_label,39384801
Chemotherapy,preferred_label,Chemotherapy,preferred_label,39384801
Angiogenesis,preferred_label,Angiogenesis,preferred_label,39384801
Sunitinib,preferred_label,Sunitinib,preferred_label,39384801
Exemestane,preferred_label,Exemestane,preferred_label,39384801
Postmenopausal women,preferred_label,Postmenopausal women,preferred_label,39384801
VEGFR2,preferred_label,VEGFR2,preferred_label,39384801
ESR1,preferred_label,ESR1,preferred_label,39384801
PGR,preferred_label,PGR,preferred_label,39384801
NAT1,preferred_label,NAT1,preferred_label,39384801
EGFR,preferred_label,EGFR,preferred_label,39384801
MYC,preferred_label,MYC,preferred_label,39384801
SFRP1,preferred_label,SFRP1,preferred_label,39384801
FOXC1,preferred_label,FOXC1,preferred_label,39384801
Luminal A subtype,preferred_label,Luminal A subtype,preferred_label,39384801
cancer treatment,treated with drug,cancer treatment,treated with drug,39384243
high dose chemotherapy,drug associated with AE,high dose chemotherapy,drug associated with AE,39384243
mucosal barrier,composed primarily of,mucosal barrier,composed primarily of,39384243
gastrointestinal tract,located_in,gastrointestinal tract,located_in,39384243
toxicity,adverse event outcome,toxicity,adverse event outcome,39384243
mucositis,adverse event occurs in,mucositis,adverse event occurs in,39384243
glucagon like peptide 1 (GLP-1),drug associated with AE,glucagon like peptide 1 (GLP-1),drug associated with AE,39384243
haematopoietic stem cell transplantation (HSCT),may_treat,haematopoietic stem cell transplantation (HSCT),may_treat,39384243
lymphoma,has disease,lymphoma,has disease,39384243
autologous HSCT,may_treat,autologous HSCT,may_treat,39384243
semaglutide,drug associated with AE,semaglutide,drug associated with AE,39384243
perioperative immunotherapy,preferred_label,perioperative immunotherapy,preferred_label,39382658
resectable non small cell lung cancer,preferred_label,resectable non small cell lung cancer,preferred_label,39382658
immune checkpoint inhibitors,preferred_label,immune checkpoint inhibitors,preferred_label,39382658
chemotherapy,preferred_label,chemotherapy,preferred_label,39382658
neoadjuvant,preferred_label,neoadjuvant,preferred_label,39382658
adjuvant,preferred_label,adjuvant,preferred_label,39382658
systematic review,preferred_label,systematic review,preferred_label,39382658
Bayesian network meta-analysis,preferred_label,Bayesian network meta-analysis,preferred_label,39382658
event-free survival,preferred_label,event-free survival,preferred_label,39382658
overall survival,preferred_label,overall survival,preferred_label,39382658
treatment-related adverse events,preferred_label,treatment-related adverse events,preferred_label,39382658
PD-L1,preferred_label,PD-L1,preferred_label,39382658
COVID-19,preferred_label,COVID-19,preferred_label,39377592
PD-1 PD-L1 inhibitor therapy,preferred_label,PD-1 PD-L1 inhibitor therapy,preferred_label,39377592
cancer patients,preferred_label,cancer patients,preferred_label,39377592
immune related adverse events (irAEs),preferred_label,immune related adverse events (irAEs),preferred_label,39377592
axitinib,drug,axitinib,drug,39377544
vascular endothelial growth factor receptors,protein,vascular endothelial growth factor receptors,protein,39377544
vegfrs,protein,vegfrs,protein,39377544
renal cell carcinoma,disease,renal cell carcinoma,disease,39377544
glioblastoma,disease,glioblastoma,disease,39377544
idh wild type gbm,disease,idh wild type gbm,disease,39377544
brain tumor,disease,brain tumor,disease,39377544
glioma stem cells,cell,glioma stem cells,cell,39377544
n acetyl l cysteine,drug,n acetyl l cysteine,drug,39377544
cannabis extract,preferred_label,cannabis extract,preferred_label,39375818
nanoemulsion,preferred_label,nanoemulsion,preferred_label,39375818
9-tetrahydrocannabinol (THC),preferred_label,9-tetrahydrocannabinol (THC),preferred_label,39375818
cannabidiol (CBD),preferred_label,cannabidiol (CBD),preferred_label,39375818
glioblastoma,preferred_label,glioblastoma,preferred_label,39375818
animal model,preferred_label,animal model,preferred_label,39375818
C6 tumor model,preferred_label,C6 tumor model,preferred_label,39375818
rats,preferred_label,rats,preferred_label,39375818
hemocompatibility factors,preferred_label,hemocompatibility factors,preferred_label,39375818
cytotoxicity,preferred_label,cytotoxicity,preferred_label,39375818
MRI,preferred_label,MRI,preferred_label,39375818
tumor volume,preferred_label,tumor volume,preferred_label,39375818
survival time,preferred_label,survival time,preferred_label,39375818
adverse effects,preferred_label,adverse effects,preferred_label,39375818
anlotinib,preferred_label,anlotinib,preferred_label,39375657
docetaxel,preferred_label,docetaxel,preferred_label,39375657
epirubicin,preferred_label,epirubicin,preferred_label,39375657
cyclophosphamide,preferred_label,cyclophosphamide,preferred_label,39375657
locally advanced tnbc,preferred_label,locally advanced tnbc,preferred_label,39375657
neoadjuvant chemotherapy regimen,preferred_label,neoadjuvant chemotherapy regimen,preferred_label,39375657
patients,preferred_label,patients,preferred_label,39375657
systemic treatment,preferred_label,systemic treatment,preferred_label,39375657
surgery,preferred_label,surgery,preferred_label,39375657
therapeutic regimen,preferred_label,therapeutic regimen,preferred_label,39375657
adverse events,preferred_label,adverse events,preferred_label,39375657
neutropenia,preferred_label,neutropenia,preferred_label,39375657
palmar plantar erythrodysesthesia syndrome,preferred_label,palmar plantar erythrodysesthesia syndrome,preferred_label,39375657
antitumor activity,preferred_label,antitumor activity,preferred_label,39375657
metastatic pancreatic ductal adenocarcinoma,class_id,metastatic pancreatic ductal adenocarcinoma,class_id,39369582
pharmacological ascorbate,preferred_label,pharmacological ascorbate,preferred_label,39369582
vitamin c,synonyms,vitamin c,synonyms,39369582
gemcitabine,preferred_label,gemcitabine,preferred_label,39369582
nab paclitaxel,preferred_label,nab paclitaxel,preferred_label,39369582
overall survival,semantic_types,overall survival,semantic_types,39369582
progression free survival,semantic_types,progression free survival,semantic_types,39369582
adverse event incidence,semantic_types,adverse event incidence,semantic_types,39369582
quality of life,semantic_types,quality of life,semantic_types,39369582
patient reported outcomes,semantic_types,patient reported outcomes,semantic_types,39369582
immune checkpoint inhibitors,drug,immune checkpoint inhibitors,drug,39368044
older adults,patient population,older adults,patient population,39368044
immune related adverse events,adverse event,immune related adverse events,adverse event,39368044
ageing population,patient population,ageing population,patient population,39368044
clinical trials,research study,clinical trials,research study,39368044
frailty,clinical characteristic,frailty,clinical characteristic,39368044
corticosteroids,drug,corticosteroids,drug,39368044
immune ageing,biological process,immune ageing,biological process,39368044
biomarkers,measurement,biomarkers,measurement,39368044
real world data,data source,real world data,data source,39368044
geriatric oncology population,patient population,geriatric oncology population,patient population,39368044
anaplastic meningiomas,class_id,anaplastic meningiomas,class_id,39358739
who grade 3 tumors,preferred_label,who grade 3 tumors,preferred_label,39358739
recurrent anaplastic meningioma,preferred_label,recurrent anaplastic meningioma,preferred_label,39358739
surgery,preferred_label,surgery,preferred_label,39358739
radiation,preferred_label,radiation,preferred_label,39358739
local control,preferred_label,local control,preferred_label,39358739
progression-free survival,preferred_label,progression-free survival,preferred_label,39358739
treatment-related adverse events,preferred_label,treatment-related adverse events,preferred_label,39358739
bevacizumab,preferred_label,bevacizumab,preferred_label,39358739
radiation necrosis,preferred_label,radiation necrosis,preferred_label,39358739
cdkn2a homozygote deletion,preferred_label,cdkn2a homozygote deletion,preferred_label,39358739
risk of local failure,preferred_label,risk of local failure,preferred_label,39358739
symptomatic radiation necrosis,preferred_label,symptomatic radiation necrosis,preferred_label,39358739
re-irradiation,preferred_label,re-irradiation,preferred_label,39358739
toxicity,preferred_label,toxicity,preferred_label,39358739
individualized treatment approaches,preferred_label,individualized treatment approaches,preferred_label,39358739
further research,preferred_label,further research,preferred_label,39358739
management strategies,preferred_label,management strategies,preferred_label,39358739
challenging disease,preferred_label,challenging disease,preferred_label,39358739
advanced intrahepatic cholangiocarcinoma,class_id,advanced intrahepatic cholangiocarcinoma,class_id,39358645
lenvatinib plus toripalimab,preferred_label,lenvatinib plus toripalimab,preferred_label,39358645
pd 1 antibody,synonyms,pd 1 antibody,synonyms,39358645
chemo free therapy,semantic_types,chemo free therapy,semantic_types,39358645
overall survival,preferred_label,overall survival,preferred_label,39358645
progression free survival,preferred_label,progression free survival,preferred_label,39358645
objective response rate,preferred_label,objective response rate,preferred_label,39358645
disease control rate,preferred_label,disease control rate,preferred_label,39358645
adverse events,preferred_label,adverse events,preferred_label,39358645
baseline ca19 9 levels,preferred_label,baseline ca19 9 levels,preferred_label,39358645
idh1 mutations,preferred_label,idh1 mutations,preferred_label,39358645
akt,class_id,akt,class_id,39353238
cell survival,preferred_label,cell survival,preferred_label,39353238
proliferation,preferred_label,proliferation,preferred_label,39353238
metabolism,preferred_label,metabolism,preferred_label,39353238
small molecule akt inhibitors,preferred_label,small molecule akt inhibitors,preferred_label,39353238
cancer,preferred_label,cancer,preferred_label,39353238
inflammatory diseases,preferred_label,inflammatory diseases,preferred_label,39353238
atp competitive and allosteric modulators,preferred_label,atp competitive and allosteric modulators,preferred_label,39353238
preclinical and clinical development,preferred_label,preclinical and clinical development,preferred_label,39353238
specificity,preferred_label,specificity,preferred_label,39353238
bioavailability,preferred_label,bioavailability,preferred_label,39353238
toxicity,preferred_label,toxicity,preferred_label,39353238
pharmacokinetic properties,preferred_label,pharmacokinetic properties,preferred_label,39353238
efficacy,preferred_label,efficacy,preferred_label,39353238
safety profile,preferred_label,safety profile,preferred_label,39353238
therapeutic window,preferred_label,therapeutic window,preferred_label,39353238
dosing,preferred_label,dosing,preferred_label,39353238
adverse effects,preferred_label,adverse effects,preferred_label,39353238
cisplatin plus gemcitabine,drug,cisplatin plus gemcitabine,drug,39353216
nivolumab plus lenvatinib,drug combination,nivolumab plus lenvatinib,drug combination,39353216
advanced biliary tract cancer,disease,advanced biliary tract cancer,disease,39353216
myocarditis,adverse event,myocarditis,adverse event,39353216
hypertension,adverse event,hypertension,adverse event,39353216
biliary tract infection,adverse event,biliary tract infection,adverse event,39353216
rash,adverse event,rash,adverse event,39353216
hypothyroidism,adverse event,hypothyroidism,adverse event,39353216
melanoma,preferred_label,melanoma,preferred_label,39353049
nitric oxide,preferred_label,nitric oxide,preferred_label,39353049
immunotherapies,preferred_label,immunotherapies,preferred_label,39353049
skin cancer,preferred_label,skin cancer,preferred_label,39353049
chemical no donors,preferred_label,chemical no donors,preferred_label,39353049
macromolecular no donor systems,preferred_label,macromolecular no donor systems,preferred_label,39353049
cyclodextrin,preferred_label,cyclodextrin,preferred_label,39353049
mesoporous silica nanoparticles,preferred_label,mesoporous silica nanoparticles,preferred_label,39353049
hyaluronic acid,preferred_label,hyaluronic acid,preferred_label,39353049
skin cells,preferred_label,skin cells,preferred_label,39353049
tumor growth,preferred_label,tumor growth,preferred_label,39353049
older adults,class_id,older adults,class_id,39357051
cancer treatment,class_id,cancer treatment,class_id,39357051
adverse events,class_id,adverse events,class_id,39357051
chemotherapy induced nausea and vomiting (CINV),class_id,chemotherapy induced nausea and vomiting (CINV),class_id,39357051
serious game (Managing at Home - MAH),class_id,serious game (Managing at Home - MAH),class_id,39357051
intervention group,class_id,intervention group,class_id,39357051
control group,class_id,control group,class_id,39357051
baseline (T1),class_id,baseline (T1),class_id,39357051
completion of the study (T6),class_id,completion of the study (T6),class_id,39357051
follow up visit (T2-T6),class_id,follow up visit (T2-T6),class_id,39357051
older adults receiving cancer-related chemotherapy,class_id,older adults receiving cancer-related chemotherapy,class_id,39357051
randomized clinical trial,class_id,randomized clinical trial,class_id,39357051
data collection and analysis,class_id,data collection and analysis,class_id,39357051
simulation and gaming technology,class_id,simulation and gaming technology,class_id,39357051
p glycoprotein,class_id,p glycoprotein,class_id,39356462
breast cancer resistance protein,class_id,breast cancer resistance protein,class_id,39356462
efflux transporters,preferred_label,efflux transporters,preferred_label,39356462
testis,preferred_label,testis,preferred_label,39356462
reproductive toxicity in males,preferred_label,reproductive toxicity in males,preferred_label,39356462
spermatogenesis,preferred_label,spermatogenesis,preferred_label,39356462
anti tumor agents,preferred_label,anti tumor agents,preferred_label,39356462
blood testis barrier,preferred_label,blood testis barrier,preferred_label,39356462
high dose methotrexate,drug,high dose methotrexate,drug,39356310
delayed methotrexate elimination,adverse event,delayed methotrexate elimination,adverse event,39356310
renal dysfunction,adverse event,renal dysfunction,adverse event,39356310
life threatening toxicity,adverse event,life threatening toxicity,adverse event,39356310
glucarpidase,drug,glucarpidase,drug,39356310
hyperhydration,supportive measure,hyperhydration,supportive measure,39356310
urine alkalinization,supportive measure,urine alkalinization,supportive measure,39356310
leucovorin rescue,treatment,leucovorin rescue,treatment,39356310
intensified hydration,treatment,intensified hydration,treatment,39356310
high dose leucovorin,treatment,high dose leucovorin,treatment,39356310
5 arylaminouracil derivatives,class_id,5 arylaminouracil derivatives,class_id,39355889
hiv 1,preferred_label,hiv 1,preferred_label,39355889
herpesviruses,preferred_label,herpesviruses,preferred_label,39355889
mycobacteria,preferred_label,mycobacteria,preferred_label,39355889
leukemia,preferred_label,leukemia,preferred_label,39355889
neuroblastoma,preferred_label,neuroblastoma,preferred_label,39355889
glial brain tumors,preferred_label,glial brain tumors,preferred_label,39355889
5 aminouracils,class_id,5 aminouracils,class_id,39355889
neuroblastoma cell lines,class_id,neuroblastoma cell lines,class_id,39355889
k 562 lymphoblastic cells,class_id,k 562 lymphoblastic cells,class_id,39355889
hl 60 promyeoloblastic cells,class_id,hl 60 promyeoloblastic cells,class_id,39355889
glioblastoma multiforme,preferred_label,glioblastoma multiforme,preferred_label,39355889
gbm5522,class_id,gbm5522,class_id,39355889
gbm6138,class_id,gbm6138,class_id,39355889
isopropylphenylamine uracil,class_id,isopropylphenylamine uracil,class_id,39355889
tert butylphenylamine uracil,class_id,tert butylphenylamine uracil,class_id,39355889
half maximal inhibitory concentrations (IC50),preferred_label,half maximal inhibitory concentrations (IC50),preferred_label,39355889
fluoropyrimidines,drug,fluoropyrimidines,drug,39350200
solid tumors,disease,solid tumors,disease,39350200
dihydropyrimidine dehydrogenase,enzyme,dihydropyrimidine dehydrogenase,enzyme,39350200
dpyd gene,gene,dpyd gene,gene,39350200
genetic mutations,mutation,genetic mutations,mutation,39350200
pyrimidine metabolism,metabolic process,pyrimidine metabolism,metabolic process,39350200
toxicity,adverse event outcome,toxicity,adverse event outcome,39350200
cancer patients,patient,cancer patients,patient,39350200
treatment related mortality,outcome,treatment related mortality,outcome,39350200
dpyd deficiency,mutation,dpyd deficiency,mutation,39350200
dpyd variants,mutation,dpyd variants,mutation,39350200
immune checkpoint inhibitors,preferred_label,immune checkpoint inhibitors,preferred_label,39348984
metastatic urothelial carcinoma,preferred_label,metastatic urothelial carcinoma,preferred_label,39348984
immune related adverse events,preferred_label,immune related adverse events,preferred_label,39348984
neutrophil to lymphocyte ratio,preferred_label,neutrophil to lymphocyte ratio,preferred_label,39348984
systemic immune inflammation index,preferred_label,systemic immune inflammation index,preferred_label,39348984
platelet to lymphocyte ratio,preferred_label,platelet to lymphocyte ratio,preferred_label,39348984
cisplatin,drug,cisplatin,drug,39348265
acute kidney injury,adverse event,acute kidney injury,adverse event,39348265
chemoradiotherapy,treatment,chemoradiotherapy,treatment,39348265
head and neck cancer,disease,head and neck cancer,disease,39348265
dual inhibition,preferred_label,dual inhibition,preferred_label,39343510
anti programmed death 1,preferred_label,anti programmed death 1,preferred_label,39343510
anti cytotoxic t lymphocyte antigen 4,preferred_label,anti cytotoxic t lymphocyte antigen 4,preferred_label,39343510
checkpoint inhibitors,preferred_label,checkpoint inhibitors,preferred_label,39343510
cancers,preferred_label,cancers,preferred_label,39343510
rare solid cancers,preferred_label,rare solid cancers,preferred_label,39343510
desmoid tumors,preferred_label,desmoid tumors,preferred_label,39343510
surgery,preferred_label,surgery,preferred_label,39343510
ipilimumab,preferred_label,ipilimumab,preferred_label,39343510
nivolumab,preferred_label,nivolumab,preferred_label,39343510
swog s1609,preferred_label,swog s1609,preferred_label,39343510
dart trial,preferred_label,dart trial,preferred_label,39343510
prospective open label multicenter,preferred_label,prospective open label multicenter,preferred_label,39343510
response evaluation criteria in solid tumors,preferred_label,response evaluation criteria in solid tumors,preferred_label,39343510
progression free survival,preferred_label,progression free survival,preferred_label,39343510
overall survival,preferred_label,overall survival,preferred_label,39343510
clinical benefit rate,preferred_label,clinical benefit rate,preferred_label,39343510
stable disease,preferred_label,stable disease,preferred_label,39343510
toxicity,preferred_label,toxicity,preferred_label,39343510
adverse events,preferred_label,adverse events,preferred_label,39343510
fatigue,preferred_label,fatigue,preferred_label,39343510
nausea,preferred_label,nausea,preferred_label,39343510
hypothyroidism,preferred_label,hypothyroidism,preferred_label,39343510
cervical cancer,preferred_label,cervical cancer,preferred_label,39342591
brachytherapy,preferred_label,brachytherapy,preferred_label,39342591
cisplatin,preferred_label,cisplatin,preferred_label,39342591
chemoradiation,preferred_label,chemoradiation,preferred_label,39342591
ebrt,preferred_label,ebrt,preferred_label,39342591
concomitant chemotherapy,preferred_label,concomitant chemotherapy,preferred_label,39342591
clinical trial,preferred_label,clinical trial,preferred_label,39342591
response rate,preferred_label,response rate,preferred_label,39342591
side effects,preferred_label,side effects,preferred_label,39342591
palbociclib,drug,palbociclib,drug,39342581
ribociclib,drug,ribociclib,drug,39342581
breast cancer,disease,breast cancer,disease,39342581
fulvestrant,drug,fulvestrant,drug,39342581
EORTC,organization,EORTC,organization,39342581
CTCAE,scale,CTCAE,scale,39342581
goserelin,drug,goserelin,drug,39342581
colorectal cancer,class_id,colorectal cancer,class_id,39339648
5-fluorouracil,preferred_label,5-fluorouracil,preferred_label,39339648
taurine,preferred_label,taurine,preferred_label,39339648
adenocarcinoma,preferred_label,adenocarcinoma,preferred_label,39339648
"1,2-dimethylhydrazine",preferred_label,"1,2-dimethylhydrazine",preferred_label,39339648
rats,preferred_label,rats,preferred_label,39339648
genes,preferred_label,genes,preferred_label,39339648
APC-catenin,preferred_label,APC-catenin,preferred_label,39339648
hepatocellular carcinoma,class_id,hepatocellular carcinoma,class_id,39339402
sorafenib,preferred_label,sorafenib,preferred_label,39339402
lenvatinib,preferred_label,lenvatinib,preferred_label,39339402
nanotechnology,preferred_label,nanotechnology,preferred_label,39339402
nanocarriers,preferred_label,nanocarriers,preferred_label,39339402
chemotherapeutic agents,preferred_label,chemotherapeutic agents,preferred_label,39339402
gene therapy,preferred_label,gene therapy,preferred_label,39339402
phototherapy,preferred_label,phototherapy,preferred_label,39339402
immunotherapy,preferred_label,immunotherapy,preferred_label,39339402
Immune checkpoint inhibitors,drug,Immune checkpoint inhibitors,drug,39334098
Proton pump inhibitors,drug,Proton pump inhibitors,drug,39334098
Concomitant treatment,procedure,Concomitant treatment,procedure,39334098
US Food and Drug Administration Adverse Event Reporting System,system,US Food and Drug Administration Adverse Event Reporting System,system,39334098
Congenital disorders,disease,Congenital disorders,disease,39334098
Familial disorders,disease,Familial disorders,disease,39334098
Genetic disorders,disease,Genetic disorders,disease,39334098
Hepatobiliary disorders,disease,Hepatobiliary disorders,disease,39334098
Metabolism disorders,disease,Metabolism disorders,disease,39334098
Nutrition disorders,disease,Nutrition disorders,disease,39334098
Skin disorders,disease,Skin disorders,disease,39334098
Subcutaneous tissue disorders,disease,Subcutaneous tissue disorders,disease,39334098
Programmed death 1,protein,Programmed death 1,protein,39334098
Programmed death ligand 1,protein,Programmed death ligand 1,protein,39334098
Cytotoxic T lymphocyte antigen 4,protein,Cytotoxic T lymphocyte antigen 4,protein,39334098
MedDRA query system organ class toxicities,system,MedDRA query system organ class toxicities,system,39334098
lenvatinib,drug,lenvatinib,drug,39333610
patients,class_id,patients,class_id,39333610
hepatocellular carcinoma,disease,hepatocellular carcinoma,disease,39333610
muscle loss,adverse event,muscle loss,adverse event,39333610
Germany,location,Germany,location,39333610
adc,drug,adc,drug,39333227
immune checkpoint inhibitors,drug,immune checkpoint inhibitors,drug,39333227
cancer,disease,cancer,disease,39333227
efficacy,outcome,efficacy,outcome,39333227
safety,outcome,safety,outcome,39333227
combination therapy,treatment,combination therapy,treatment,39333227
meta analysis,study type,meta analysis,study type,39333227
ORR,outcome measure,ORR,outcome measure,39333227
adverse effects,outcome measure,adverse effects,outcome measure,39333227
Hodgkin lymphoma,disease,Hodgkin lymphoma,disease,39333227
Non-Hodgkin lymphoma,disease,Non-Hodgkin lymphoma,disease,39333227
peripheral neuropathy,adverse event,peripheral neuropathy,adverse event,39333227
skin adverse effects,adverse event,skin adverse effects,adverse event,39333227
digestive system adverse effects,adverse event,digestive system adverse effects,adverse event,39333227
egfr targeted therapies,drug,egfr targeted therapies,drug,39330834
urokinase type plasminogen activator receptor (upar) targeted drugs,drug,urokinase type plasminogen activator receptor (upar) targeted drugs,drug,39330834
recombinant ebat,drug,recombinant ebat,drug,39330834
cytokines egf,drug,cytokines egf,drug,39330834
upar knockout mice,class_id,upar knockout mice,class_id,39330834
immunocompetent mice,class_id,immunocompetent mice,class_id,39330834
tumor bearing mice,class_id,tumor bearing mice,class_id,39330834
dogs with spontaneous sarcoma,class_id,dogs with spontaneous sarcoma,class_id,39330834
individuals with sarcoma,class_id,individuals with sarcoma,class_id,39330834
other cancers,class_id,other cancers,class_id,39330834
surufatinib,preferred_label,surufatinib,preferred_label,39327433
antiangiogenic therapy,semantic_types,antiangiogenic therapy,semantic_types,39327433
toripalimab,preferred_label,toripalimab,preferred_label,39327433
etoposide,preferred_label,etoposide,preferred_label,39327433
cisplatin,preferred_label,cisplatin,preferred_label,39327433
small cell lung cancer,semantic_types,small cell lung cancer,semantic_types,39327433
progression free survival,preferred_label,progression free survival,preferred_label,39327433
objective response rate,preferred_label,objective response rate,preferred_label,39327433
disease control rate,preferred_label,disease control rate,preferred_label,39327433
overall survival,preferred_label,overall survival,preferred_label,39327433
adverse events,semantic_types,adverse events,semantic_types,39327433
neutrophil count decreased,preferred_label,neutrophil count decreased,preferred_label,39327433
white blood cell count decreased,preferred_label,white blood cell count decreased,preferred_label,39327433
platelet count decreased,preferred_label,platelet count decreased,preferred_label,39327433
chromosomal aberrations,preferred_label,chromosomal aberrations,preferred_label,39326941
bleomycin,preferred_label,bleomycin,preferred_label,39326941
human lymphoblastoid cells,preferred_label,human lymphoblastoid cells,preferred_label,39326941
epstein barr virus,preferred_label,epstein barr virus,preferred_label,39326941
t 37,preferred_label,t 37,preferred_label,39326941
acentric fragments,preferred_label,acentric fragments,preferred_label,39326941
interstitial deletions,preferred_label,interstitial deletions,preferred_label,39326941
incomplete chromosomes,preferred_label,incomplete chromosomes,preferred_label,39326941
nqbio 06,synthetic carboline alkaloid,nqbio 06,synthetic carboline alkaloid,39326936
nqbio 21,synthetic carboline alkaloid,nqbio 21,synthetic carboline alkaloid,39326936
ovarian cancer cell line tov 21 g,cancer cell line,ovarian cancer cell line tov 21 g,cancer cell line,39326936
MDA-MB-231 breast cancer cells,cancer cell line,MDA-MB-231 breast cancer cells,cancer cell line,39326936
chromosomal breaks,genotoxic effect,chromosomal breaks,genotoxic effect,39326936
micronucleus assay,mutagenic effect,micronucleus assay,mutagenic effect,39326936
lipinski's rules,criteria for drug-likeness,lipinski's rules,criteria for drug-likeness,39326936
intestinal absorption,ADME parameter,intestinal absorption,ADME parameter,39326936
p-glycoprotein,transporter protein,p-glycoprotein,transporter protein,39326936
amivantamab,preferred_label,amivantamab,preferred_label,39324708
epidermal growth factor receptor,preferred_label,epidermal growth factor receptor,preferred_label,39324708
met,preferred_label,met,preferred_label,39324708
non small cell lung cancer,preferred_label,non small cell lung cancer,preferred_label,39324708
cutaneous toxicities,preferred_label,cutaneous toxicities,preferred_label,39324708
egfr inhibition,preferred_label,egfr inhibition,preferred_label,39324708
rash,preferred_label,rash,preferred_label,39324708
paronychia,preferred_label,paronychia,preferred_label,39324708
dermatitis acneiform,preferred_label,dermatitis acneiform,preferred_label,39324708
nurses,preferred_label,nurses,preferred_label,39324708
advanced practice providers,preferred_label,advanced practice providers,preferred_label,39324708
physicians,preferred_label,physicians,preferred_label,39324708
comedications,preferred_label,comedications,preferred_label,39324708
immune checkpoint inhibitors,preferred_label,immune checkpoint inhibitors,preferred_label,39320566
melanoma,preferred_label,melanoma,preferred_label,39320566
lung cancer,preferred_label,lung cancer,preferred_label,39320566
patients,preferred_label,patients,preferred_label,39320566
caregivers,preferred_label,caregivers,preferred_label,39320566
side effects,preferred_label,side effects,preferred_label,39320566
oncologist,preferred_label,oncologist,preferred_label,39320566
tyrosine kinase inhibitors,drug,tyrosine kinase inhibitors,drug,39318033
cardiac side effects,adverse event,cardiac side effects,adverse event,39318033
extracellular vesicles,preferred_label,extracellular vesicles,preferred_label,39316382
bleb nanovesicles,preferred_label,bleb nanovesicles,preferred_label,39316382
human fc receptor i (hcd64),preferred_label,human fc receptor i (hcd64),preferred_label,39316382
monomeric igg,preferred_label,monomeric igg,preferred_label,39316382
prostate cancer,preferred_label,prostate cancer,preferred_label,39316382
prostate specific membrane antigen (psma),preferred_label,prostate specific membrane antigen (psma),preferred_label,39316382
osteosarcoma,class_id,osteosarcoma,class_id,39315544
gemcitabine and docetaxel combination chemotherapy,preferred_label,gemcitabine and docetaxel combination chemotherapy,preferred_label,39315544
gemdox,synonyms,gemdox,synonyms,39315544
mg 63,class_id,mg 63,class_id,39315544
hos 143b,class_id,hos 143b,class_id,39315544
neutropenia,preferred_label,neutropenia,preferred_label,39315544
thrombocytopenia,preferred_label,thrombocytopenia,preferred_label,39315544
anaemia,preferred_label,anaemia,preferred_label,39315544
cisplatin resistant models,preferred_label,cisplatin resistant models,preferred_label,39315544
doxorubicin,preferred_label,doxorubicin,preferred_label,39315544
methotrexate,preferred_label,methotrexate,preferred_label,39315544
clinical trials,preferred_label,clinical trials,preferred_label,39315544
immune checkpoint inhibitors,preferred_label,immune checkpoint inhibitors,preferred_label,39311981
anti cytotoxic t lymphocyte associated protein 4,preferred_label,anti cytotoxic t lymphocyte associated protein 4,preferred_label,39311981
anti programmed cell death 1 programmed cell death ligand 1,preferred_label,anti programmed cell death 1 programmed cell death ligand 1,preferred_label,39311981
gastrointestinal immune related adverse events,preferred_label,gastrointestinal immune related adverse events,preferred_label,39311981
diarrhea,preferred_label,diarrhea,preferred_label,39311981
colitis,preferred_label,colitis,preferred_label,39311981
immune mediated diarrhea and colitis,preferred_label,immune mediated diarrhea and colitis,preferred_label,39311981
imdc,preferred_label,imdc,preferred_label,39311981
baseline gut microbiota,preferred_label,baseline gut microbiota,preferred_label,39311981
inflammatory bowel disease,preferred_label,inflammatory bowel disease,preferred_label,39311981
corticosteroids,preferred_label,corticosteroids,preferred_label,39311981
infliximab,preferred_label,infliximab,preferred_label,39311981
vedolizumab,preferred_label,vedolizumab,preferred_label,39311981
microbiota transplantation,preferred_label,microbiota transplantation,preferred_label,39311981
cytokines,preferred_label,cytokines,preferred_label,39311981
lymphocyte replication inhibitors,preferred_label,lymphocyte replication inhibitors,preferred_label,39311981
nanotechnology,preferred_label,nanotechnology,preferred_label,39308042
cancer treatments,preferred_label,cancer treatments,preferred_label,39308042
chemotherapy resistance,preferred_label,chemotherapy resistance,preferred_label,39308042
toxic drugs,preferred_label,toxic drugs,preferred_label,39308042
silver nanoparticles,preferred_label,silver nanoparticles,preferred_label,39308042
agnps,synonyms,agnps,synonyms,39308042
antimicrobial properties,preferred_label,antimicrobial properties,preferred_label,39308042
antiproliferative properties,preferred_label,antiproliferative properties,preferred_label,39308042
nanotoxicological assessment,preferred_label,nanotoxicological assessment,preferred_label,39308042
tamoxifen,preferred_label,tamoxifen,preferred_label,39308042
mcf 7,preferred_label,mcf 7,preferred_label,39308042
mda mb 231,preferred_label,mda mb 231,preferred_label,39308042
breast tumor cells,preferred_label,breast tumor cells,preferred_label,39308042
compusyn software,preferred_label,compusyn software,preferred_label,39308042
combination index,preferred_label,combination index,preferred_label,39308042
cytotoxic effect,preferred_label,cytotoxic effect,preferred_label,39308042
antiproliferative effect,preferred_label,antiproliferative effect,preferred_label,39308042
cell migration,preferred_label,cell migration,preferred_label,39308042
reactive oxygen species production,preferred_label,reactive oxygen species production,preferred_label,39308042
genotoxic effect,preferred_label,genotoxic effect,preferred_label,39308042
proapoptotic gene expression,preferred_label,proapoptotic gene expression,preferred_label,39308042
oxidative stress gene expression,preferred_label,oxidative stress gene expression,preferred_label,39308042
internalization,preferred_label,internalization,preferred_label,39308042
breast cancer cells,preferred_label,breast cancer cells,preferred_label,39308042
chemotherapeutic agents,preferred_label,chemotherapeutic agents,preferred_label,39308042
oncology therapy,preferred_label,oncology therapy,preferred_label,39308042
selinexor,drug,selinexor,drug,39307725
venetoclax,drug,venetoclax,drug,39307725
azactitidine,drug,azactitidine,drug,39307725
acute myeloid leukemia,disease,acute myeloid leukemia,disease,39307725
complete remission,clinical outcome,complete remission,clinical outcome,39307725
partial remission,clinical outcome,partial remission,clinical outcome,39307725
hematological toxicity,adverse event,hematological toxicity,adverse event,39307725
malignant tumors,class_id,malignant tumors,class_id,39307710
cancer patients,class_id,cancer patients,class_id,39307710
cardiovascular toxicity,class_id,cardiovascular toxicity,class_id,39307710
cardio oncology,class_id,cardio oncology,class_id,39307710
cardiac biomarkers,class_id,cardiac biomarkers,class_id,39307710
cardiovascular diseases,class_id,cardiovascular diseases,class_id,39307710
immune checkpoint inhibitors,preferred_label,immune checkpoint inhibitors,preferred_label,39307038
esophageal squamous cell carcinoma,preferred_label,esophageal squamous cell carcinoma,preferred_label,39307038
camrelizumab,preferred_label,camrelizumab,preferred_label,39307038
apatinib,preferred_label,apatinib,preferred_label,39307038
patients,preferred_label,patients,preferred_label,39307038
disease progression,preferred_label,disease progression,preferred_label,39307038
phase II study,preferred_label,phase II study,preferred_label,39307038
treatment,preferred_label,treatment,preferred_label,39307038
adverse events,preferred_label,adverse events,preferred_label,39307038
sacituzumab govitecan,drug,sacituzumab govitecan,drug,39302614
breast cancer,disease,breast cancer,disease,39302614
Japanese patients,patient,Japanese patients,patient,39302614
triple negative breast cancer,disease,triple negative breast cancer,disease,39302614
transaminases,biomarker,transaminases,biomarker,39302614
progression free survival,outcome,progression free survival,outcome,39302614
overall survival,outcome,overall survival,outcome,39302614
drug induced pneumonitis,adverse event,drug induced pneumonitis,adverse event,39302574
lung cancer systemic therapy,treatment,lung cancer systemic therapy,treatment,39302574
immunotherapy,treatment,immunotherapy,treatment,39302574
chemotherapy,treatment,chemotherapy,treatment,39302574
targeted therapy,treatment,targeted therapy,treatment,39302574
immune checkpoint inhibitors,drug,immune checkpoint inhibitors,drug,39302574
corticosteroids,drug,corticosteroids,drug,39302574
ibrutinib,drug,ibrutinib,drug,39300447
lenalidomide,drug,lenalidomide,drug,39300447
primary central nervous system lymphoma,disease,primary central nervous system lymphoma,disease,39300447
methotrexate,drug,methotrexate,drug,39300447
rituximab,drug,rituximab,drug,39300447
procarbazine,drug,procarbazine,drug,39300447
vincristine,drug,vincristine,drug,39300447
prednisone,drug,prednisone,drug,39300447
aspergillosis,adverse event,aspergillosis,adverse event,39300447
pneumocystosis,adverse event,pneumocystosis,adverse event,39300447
catheter related infection,adverse event,catheter related infection,adverse event,39300447
increased alanine aminotransferase levels,adverse event,increased alanine aminotransferase levels,adverse event,39300447
hepatic cytolysis,adverse event,hepatic cytolysis,adverse event,39300447
neutropenia,adverse event,neutropenia,adverse event,39300447
infections,adverse event,infections,adverse event,39300447
lyell's syndrome,adverse event,lyell's syndrome,adverse event,39300447
5 fluorouracil,drug,5 fluorouracil,drug,39300121
colorectal cancer malignancy,disease,colorectal cancer malignancy,disease,39300121
senescent cells,cellular component,senescent cells,cellular component,39300121
oleanolic acid,drug,oleanolic acid,drug,39300121
human umbilical vein endothelial cells (HUVECs),cell line,human umbilical vein endothelial cells (HUVECs),cell line,39300121
human normal intestinal epithelial cells (NCM460),cell line,human normal intestinal epithelial cells (NCM460),cell line,39300121
senescence associated proteins,biomolecule,senescence associated proteins,biomolecule,39300121
senescence associated genes,biomolecule,senescence associated genes,biomolecule,39300121
senescence associated secretory phenotypes (SASPs),biomolecule,senescence associated secretory phenotypes (SASPs),biomolecule,39300121
IL-1,biomolecule,IL-1,biomolecule,39300121
IL-6,biomolecule,IL-6,biomolecule,39300121
IL-8,biomolecule,IL-8,biomolecule,39300121
IFN,biomolecule,IFN,biomolecule,39300121
TNF,biomolecule,TNF,biomolecule,39300121
mTOR,biomolecule,mTOR,biomolecule,39300121
HCT116 cells,cell line,HCT116 cells,cell line,39300121
SW480 cells,cell line,SW480 cells,cell line,39300121
Gemox,drug,Gemox,drug,39299973
Gemcitabine,drug,Gemcitabine,drug,39299973
Oxaliplatin,drug,Oxaliplatin,drug,39299973
Sintilimab,drug,Sintilimab,drug,39299973
PD-1 receptor,class_id,PD-1 receptor,class_id,39299973
PTCL,class_id,PTCL,class_id,39299973
Hematology department,class_id,Hematology department,class_id,39299973
Second affiliated hospital of Zhejiang University School of Medicine,class_id,Second affiliated hospital of Zhejiang University School of Medicine,class_id,39299973
Autologous stem cell transplantation,procedure,Autologous stem cell transplantation,procedure,39299973
Histone deacetylase inhibitors,drug,Histone deacetylase inhibitors,drug,39299973
Adverse event,class_id,Adverse event,class_id,39299973
neurologic immune related adverse events,preferred_label,neurologic immune related adverse events,preferred_label,39298719
immune checkpoint inhibitors,preferred_label,immune checkpoint inhibitors,preferred_label,39298719
italian hospitals,preferred_label,italian hospitals,preferred_label,39298719
patients,preferred_label,patients,preferred_label,39298719
peripheral nervous system,preferred_label,peripheral nervous system,preferred_label,39298719
central nervous system,preferred_label,central nervous system,preferred_label,39298719
myocarditis,preferred_label,myocarditis,preferred_label,39298719
cerebellar ataxia,preferred_label,cerebellar ataxia,preferred_label,39298719
neuromuscular weakness,preferred_label,neuromuscular weakness,preferred_label,39298719
visual loss,preferred_label,visual loss,preferred_label,39298719
sensory disturbances,preferred_label,sensory disturbances,preferred_label,39298719
focal neurologic signs,preferred_label,focal neurologic signs,preferred_label,39298719
cognitive impairment,preferred_label,cognitive impairment,preferred_label,39298719
severe neurologic disability,preferred_label,severe neurologic disability,preferred_label,39298719
overall mortality,preferred_label,overall mortality,preferred_label,39298719
cancer progression,preferred_label,cancer progression,preferred_label,39298719
nsclc,preferred_label,nsclc,preferred_label,39298516
rhodium iii 2 benzoylpyridine thiosemicarbazone complexes,preferred_label,rhodium iii 2 benzoylpyridine thiosemicarbazone complexes,preferred_label,39298516
rh4,preferred_label,rh4,preferred_label,39298516
aft nanoparticle,preferred_label,aft nanoparticle,preferred_label,39298516
multidrug resistant nsclc,preferred_label,multidrug resistant nsclc,preferred_label,39298516
breast cancer,class_id,breast cancer,class_id,39294665
chemotherapy,class_id,chemotherapy,class_id,39294665
phytomolecules,class_id,phytomolecules,class_id,39294665
combination therapy,class_id,combination therapy,class_id,39294665
drug delivery systems,class_id,drug delivery systems,class_id,39294665
complementary and alternative medicine,class_id,complementary and alternative medicine,class_id,39294665
phytochemicals,class_id,phytochemicals,class_id,39294665
clinical trials,class_id,clinical trials,class_id,39294665
polypharmacy,preferred_label,polypharmacy,preferred_label,39294452
potentially inappropriate medications (PIM),synonyms,potentially inappropriate medications (PIM),synonyms,39294452
older adults with advanced cancer,semantic_types,older adults with advanced cancer,semantic_types,39294452
physical functional outcomes,preferred_label,physical functional outcomes,preferred_label,39294452
medication measures,preferred_label,medication measures,preferred_label,39294452
geriatric assessment domain impairment,preferred_label,geriatric assessment domain impairment,preferred_label,39294452
antineoplastic regimen,preferred_label,antineoplastic regimen,preferred_label,39294452
polypharmacy,preferred_label,polypharmacy,preferred_label,39294452
medications (meds),synonyms,medications (meds),synonyms,39294452
screening tool of older person's prescriptions (STOPP) criteria,preferred_label,screening tool of older person's prescriptions (STOPP) criteria,preferred_label,39294452
2019 Beers criteria,preferred_label,2019 Beers criteria,preferred_label,39294452
activity of daily living (ADL),preferred_label,activity of daily living (ADL),preferred_label,39294452
instrumental ADL (IADL),preferred_label,instrumental ADL (IADL),preferred_label,39294452
short physical performance battery (SPPB),preferred_label,short physical performance battery (SPPB),preferred_label,39294452
falls,preferred_label,falls,preferred_label,39294452
multivariable cluster weighted generalized estimating equations models,preferred_label,multivariable cluster weighted generalized estimating equations models,preferred_label,39294452
relevant covariates,preferred_label,relevant covariates,preferred_label,39294452
vulnerable older adults with advanced cancer,semantic_types,vulnerable older adults with advanced cancer,semantic_types,39294452
systemic treatment,preferred_label,systemic treatment,preferred_label,39294452
interventions to optimize medication use,preferred_label,interventions to optimize medication use,preferred_label,39294452
lutetium 177,preferred_label,lutetium 177,preferred_label,39293461
prostate specific membrane antigen,preferred_label,prostate specific membrane antigen,preferred_label,39293461
psma 617,preferred_label,psma 617,preferred_label,39293461
metastatic castration resistant prostate cancer,preferred_label,metastatic castration resistant prostate cancer,preferred_label,39293461
docetaxel,preferred_label,docetaxel,preferred_label,39293461
prostate adenocarcinoma,preferred_label,prostate adenocarcinoma,preferred_label,39293461
androgen deprivation therapy,preferred_label,androgen deprivation therapy,preferred_label,39293461
undetectable prostate specific antigen,preferred_label,undetectable prostate specific antigen,preferred_label,39293461
febrile neutropenia,preferred_label,febrile neutropenia,preferred_label,39293461
diarrhoea,preferred_label,diarrhoea,preferred_label,39293461
ld sclc,preferred_label,ld sclc,preferred_label,39287161
platinum etoposide chemotherapy,preferred_label,platinum etoposide chemotherapy,preferred_label,39287161
thoracic radiotherapy,preferred_label,thoracic radiotherapy,preferred_label,39287161
older patients,preferred_label,older patients,preferred_label,39287161
chemoradiotherapy,preferred_label,chemoradiotherapy,preferred_label,39287161
concurrent crt,preferred_label,concurrent crt,preferred_label,39287161
sequential crt,preferred_label,sequential crt,preferred_label,39287161
chemotherapeutic treatment cycles,preferred_label,chemotherapeutic treatment cycles,preferred_label,39287161
response rate,preferred_label,response rate,preferred_label,39287161
progression free survival (PFS),preferred_label,progression free survival (PFS),preferred_label,39287161
overall survival (OS),preferred_label,overall survival (OS),preferred_label,39287161
hematological adverse events,preferred_label,hematological adverse events,preferred_label,39287161
treatment related deaths,preferred_label,treatment related deaths,preferred_label,39287161
reduced neutrophil count,preferred_label,reduced neutrophil count,preferred_label,39287161
prospective trials,preferred_label,prospective trials,preferred_label,39287161
optimal treatment strategies,preferred_label,optimal treatment strategies,preferred_label,39287161
tumor patients,class_id,tumor patients,class_id,39286288
cardiovascular complications,class_id,cardiovascular complications,class_id,39286288
cancer therapy related cardiovascular toxicity,class_id,cancer therapy related cardiovascular toxicity,class_id,39286288
cardiotoxicity,class_id,cardiotoxicity,class_id,39286288
anticancer drugs,class_id,anticancer drugs,class_id,39286288
heart failure,class_id,heart failure,class_id,39286288
myocarditis,class_id,myocarditis,class_id,39286288
hypertension,class_id,hypertension,class_id,39286288
arrhythmias,class_id,arrhythmias,class_id,39286288
vascular toxicity,class_id,vascular toxicity,class_id,39286288
vascular endothelial dysfunction,class_id,vascular endothelial dysfunction,class_id,39286288
ferroptosis,class_id,ferroptosis,class_id,39286288
mitochondrial dysfunction,class_id,mitochondrial dysfunction,class_id,39286288
oxidative stress,class_id,oxidative stress,class_id,39286288
therapeutic measures,class_id,therapeutic measures,class_id,39286288
accumulation of anticancer drugs,class_id,accumulation of anticancer drugs,class_id,39286288
cardioprotective drugs,class_id,cardioprotective drugs,class_id,39286288
early detection,class_id,early detection,class_id,39286288
mitochondrial transplantation,class_id,mitochondrial transplantation,class_id,39286288
doxorubicin (dox),class_id,doxorubicin (dox),class_id,39286288
Metastatic Breast Cancer,has disease,Metastatic Breast Cancer,has disease,39279590
Older Women (65+),occurs in patient having disease,Older Women (65+),occurs in patient having disease,39279590
Genomics Guided Therapy,may_treat,Genomics Guided Therapy,may_treat,39279590
Biomarkers,may_diagnose,Biomarkers,may_diagnose,39279590
Systemic Anticancer Treatments,may_treat,Systemic Anticancer Treatments,may_treat,39279590
Subgroup Analyses,is evidence of,Subgroup Analyses,is evidence of,39279590
Real World Data,is evidence of,Real World Data,is evidence of,39279590
Guideline Concordance,realized in,Guideline Concordance,realized in,39279590
Comorbidity,occurs in patient having disease,Comorbidity,occurs in patient having disease,39279590
Social Supports,protects,Social Supports,protects,39279590
Malnutrition,induced_by,Malnutrition,induced_by,39279590
Frailty,may_prevent,Frailty,may_prevent,39279590
Multi-disciplinary Team,bearer of,Multi-disciplinary Team,bearer of,39279590
immune checkpoint inhibitors,drug,immune checkpoint inhibitors,drug,39277735
immune related adverse events,adverse event,immune related adverse events,adverse event,39277735
kidney,anatomical entity,kidney,anatomical entity,39277735
anti programmed cell death protein 1 (PD-1) therapy,drug,anti programmed cell death protein 1 (PD-1) therapy,drug,39277735
renal immune related adverse events (R-IRAEs),adverse event,renal immune related adverse events (R-IRAEs),adverse event,39277735
peripheral blood mononuclear cells (PBMCs),cell type,peripheral blood mononuclear cells (PBMCs),cell type,39277735
CD4+ T cells,cell type,CD4+ T cells,cell type,39277735
CD8+ T cells,cell type,CD8+ T cells,cell type,39277735
ovarian clear cell carcinoma,preferred_label,ovarian clear cell carcinoma,preferred_label,39276785
sintilimab,preferred_label,sintilimab,preferred_label,39276785
bevacizumab,preferred_label,bevacizumab,preferred_label,39276785
treatment,preferred_label,treatment,preferred_label,39276785
chemotherapy,preferred_label,chemotherapy,preferred_label,39276785
patients,preferred_label,patients,preferred_label,39276785
trial,preferred_label,trial,preferred_label,39276785
response assessment,preferred_label,response assessment,preferred_label,39276785
adverse events,preferred_label,adverse events,preferred_label,39276785
activity analysis,preferred_label,activity analysis,preferred_label,39276785
safety analysis,preferred_label,safety analysis,preferred_label,39276785
cdk4 6 inhibitors,preferred_label,cdk4 6 inhibitors,preferred_label,39267478
endocrine therapy,preferred_label,endocrine therapy,preferred_label,39267478
hormone receptor positive advanced breast cancer,preferred_label,hormone receptor positive advanced breast cancer,preferred_label,39267478
cdk4 6i therapy,preferred_label,cdk4 6i therapy,preferred_label,39267478
abemaciclib,preferred_label,abemaciclib,preferred_label,39267478
palbociclib,preferred_label,palbociclib,preferred_label,39267478
ribociclib,preferred_label,ribociclib,preferred_label,39267478
dalpiciclib,preferred_label,dalpiciclib,preferred_label,39267478
progression free survival,preferred_label,progression free survival,preferred_label,39267478
toxicity,preferred_label,toxicity,preferred_label,39267478
objective response rate,preferred_label,objective response rate,preferred_label,39267478
disease control rate,preferred_label,disease control rate,preferred_label,39267478
overall survival,preferred_label,overall survival,preferred_label,39267478
adverse events,preferred_label,adverse events,preferred_label,39267478
lung metastasis,preferred_label,lung metastasis,preferred_label,39267478
switch to endocrine therapy,preferred_label,switch to endocrine therapy,preferred_label,39267478
chemotherapy,preferred_label,chemotherapy,preferred_label,39267478
clinical benefits,preferred_label,clinical benefits,preferred_label,39267478
safety profiles,preferred_label,safety profiles,preferred_label,39267478
effective treatment strategy,preferred_label,effective treatment strategy,preferred_label,39267478
trastuzumab deruxtecan,drug,trastuzumab deruxtecan,drug,39491462
metastatic breast cancer,disease,metastatic breast cancer,disease,39491462
patients,class_id,patients,class_id,39491462
her 2 amplification,class_id,her 2 amplification,class_id,39491462
antibody drug conjugates,class_id,antibody drug conjugates,class_id,39491462
renal toxicity,adverse event,renal toxicity,adverse event,39488644
hematological toxicity,adverse event,hematological toxicity,adverse event,39488644
peptide receptor radionuclide therapy (PRRT),treatment,peptide receptor radionuclide therapy (PRRT),treatment,39488644
neuroendocrine tumor (NET),disease,neuroendocrine tumor (NET),disease,39488644
177Lu dotatate,drug,177Lu dotatate,drug,39488644
90Y dotatoc,drug,90Y dotatoc,drug,39488644
renal function,biomarker,renal function,biomarker,39488644
hematological function,biomarker,hematological function,biomarker,39488644
overall survival (OS),outcome,overall survival (OS),outcome,39488644
progression free survival (PFS),outcome,progression free survival (PFS),outcome,39488644
hepatocellular carcinoma,disease,hepatocellular carcinoma,disease,39480853
vinpocetine,drug,vinpocetine,drug,39480853
rats,organism,rats,organism,39480853
diethylnitrosamine,chemical compound,diethylnitrosamine,chemical compound,39480853
ccnd1,protein,ccnd1,protein,39480853
ki-67,protein,ki-67,protein,39480853
bcl-2,protein,bcl-2,protein,39480853
bax,protein,bax,protein,39480853
cleaved caspase 3,protein,cleaved caspase 3,protein,39480853
nf-kb,protein,nf-kb,protein,39480853
stat3,protein,stat3,protein,39480853
hif-1,protein,hif-1,protein,39480853
icam-1,protein,icam-1,protein,39480853
tgf-1,protein,tgf-1,protein,39480853
nab sirolimus,preferred_label,nab sirolimus,preferred_label,39487711
temozolomide,preferred_label,temozolomide,preferred_label,39487711
irinotecan,preferred_label,irinotecan,preferred_label,39487711
thrombocytopenia,preferred_label,thrombocytopenia,preferred_label,39487711
Ewing sarcoma,preferred_label,Ewing sarcoma,preferred_label,39487711
skin cancer,class_id,skin cancer,class_id,39485529
melanoma,class_id,melanoma,class_id,39485529
metastatic melanoma,class_id,metastatic melanoma,class_id,39485529
BRAF inhibitors,class_id,BRAF inhibitors,class_id,39485529
vemurafenib,class_id,vemurafenib,class_id,39485529
dabrafenib,class_id,dabrafenib,class_id,39485529
MEK inhibitors,class_id,MEK inhibitors,class_id,39485529
trametinib,class_id,trametinib,class_id,39485529
cobimetinib,class_id,cobimetinib,class_id,39485529
immune checkpoint inhibitors,class_id,immune checkpoint inhibitors,class_id,39485529
ipilimumab,class_id,ipilimumab,class_id,39485529
combination therapy,class_id,combination therapy,class_id,39485529
adverse event,class_id,adverse event,class_id,39485529
dermatological toxicities,class_id,dermatological toxicities,class_id,39485529
onco nephrology,preferred_label,onco nephrology,preferred_label,39482406
renal events,preferred_label,renal events,preferred_label,39482406
cancer patients,preferred_label,cancer patients,preferred_label,39482406
hematological treatments,preferred_label,hematological treatments,preferred_label,39482406
renal toxicity,preferred_label,renal toxicity,preferred_label,39482406
kidney protective measures,preferred_label,kidney protective measures,preferred_label,39482406
patients,preferred_label,patients,preferred_label,39482406
questionnaire,preferred_label,questionnaire,preferred_label,39482406
solid tumor,preferred_label,solid tumor,preferred_label,39482406
anticancer treatment,preferred_label,anticancer treatment,preferred_label,39482406
hydration,preferred_label,hydration,preferred_label,39482406
nausea,preferred_label,nausea,preferred_label,39482406
vomiting,preferred_label,vomiting,preferred_label,39482406
alkaline water,preferred_label,alkaline water,preferred_label,39482406
dehydration,preferred_label,dehydration,preferred_label,39482406
information,preferred_label,information,preferred_label,39482406
trastuzumab,drug,trastuzumab,drug,39478296
corneal ulceration,disease,corneal ulceration,disease,39478296
metastatic breast cancer,disease,metastatic breast cancer,disease,39478296
herceptin,drug,herceptin,drug,39478296
corneal ulcer,disease,corneal ulcer,disease,39478296
breast cancer,disease,breast cancer,disease,39478296
optic nerve compression,disease,optic nerve compression,disease,39478296
keratoplasty,procedure,keratoplasty,procedure,39478296
ocular surface therapy,procedure,ocular surface therapy,procedure,39478296
inavolisib,drug,inavolisib,drug,39476340
pik3ca,gene,pik3ca,gene,39476340
palbociclib,drug,palbociclib,drug,39476340
fulvestrant,drug,fulvestrant,drug,39476340
breast cancer,disease,breast cancer,disease,39476340
neutropenia,adverse event,neutropenia,adverse event,39476340
hyperglycemia,adverse event,hyperglycemia,adverse event,39476340
stomatitis,adverse event,stomatitis,adverse event,39476340
diarrhea,adverse event,diarrhea,adverse event,39476340
gefitinib,drug,gefitinib,drug,39472861
chemotherapy,treatment,chemotherapy,treatment,39472861
bevacizumab,drug,bevacizumab,drug,39472861
epidermal growth factor receptor (EGFR),gene/protein,epidermal growth factor receptor (EGFR),gene/protein,39472861
non squamous non small cell lung cancer (NSCLC),disease,non squamous non small cell lung cancer (NSCLC),disease,39472861
pemetrexed,drug,pemetrexed,drug,39472861
carboplatin,drug,carboplatin,drug,39472861
neutropenia,adverse event,neutropenia,adverse event,39472861
thrombocytopenia,adverse event,thrombocytopenia,adverse event,39472861
nausea,adverse event,nausea,adverse event,39472861
skin rash,adverse event,skin rash,adverse event,39472861
bleeding,adverse event,bleeding,adverse event,39472861
increased ALT,adverse event,increased ALT,adverse event,39472861
afatinib,drug,afatinib,drug,39471023
non small cell lung cancer,disease,non small cell lung cancer,disease,39471023
egfr mutations,genetic mutation,egfr mutations,genetic mutation,39471023
elderly patients,patient demographic,elderly patients,patient demographic,39471023
physical condition,clinical characteristic,physical condition,clinical characteristic,39471023
comorbidities,medical condition,comorbidities,medical condition,39471023
initial dosage,treatment parameter,initial dosage,treatment parameter,39471023
dose adjustments,treatment parameter,dose adjustments,treatment parameter,39471023
retrospective analysis,study design,retrospective analysis,study design,39471023
cancer centers,medical facility,cancer centers,medical facility,39471023
brain metastases,medical condition,brain metastases,medical condition,39471023
adverse effects,side effect,adverse effects,side effect,39471023
response rate,clinical parameter,response rate,clinical parameter,39471023
neoadjuvant chemotherapy,preferred_label,neoadjuvant chemotherapy,preferred_label,39468597
ovarian cancer,preferred_label,ovarian cancer,preferred_label,39468597
nanoparticle albumin bound paclitaxel,preferred_label,nanoparticle albumin bound paclitaxel,preferred_label,39468597
carboplatin,preferred_label,carboplatin,preferred_label,39468597
unresectable oc,preferred_label,unresectable oc,preferred_label,39468597
phase ib ii study,preferred_label,phase ib ii study,preferred_label,39468597
patients,preferred_label,patients,preferred_label,39468597
surgery,preferred_label,surgery,preferred_label,39468597
adverse events,preferred_label,adverse events,preferred_label,39468597
nivolumab,drug,nivolumab,drug,39468513
chemotherapy,drug,chemotherapy,drug,39468513
gastric cancer,disease,gastric cancer,disease,39468513
her2,gene,her2,gene,39468513
programmed cell death ligand 1,protein,programmed cell death ligand 1,protein,39468513
neutropenia,adverse event,neutropenia,adverse event,39468513
thrombocytopenia,adverse event,thrombocytopenia,adverse event,39468513
diarrhea,adverse event,diarrhea,adverse event,39468513
anemia,adverse event,anemia,adverse event,39468513
Head and Neck Squamous Cell Carcinoma,class_id,Head and Neck Squamous Cell Carcinoma,class_id,39467871
Cisplatin-based Chemoradiotherapy,class_id,Cisplatin-based Chemoradiotherapy,class_id,39467871
Toxicities,preferred_label,Toxicities,preferred_label,39467871
Skeletal Muscle Mass,preferred_label,Skeletal Muscle Mass,preferred_label,39467871
Patients,preferred_label,Patients,preferred_label,39467871
Qualitative Study,preferred_label,Qualitative Study,preferred_label,39467871
Interviews,preferred_label,Interviews,preferred_label,39467871
Topic Guide,preferred_label,Topic Guide,preferred_label,39467871
Thematic Analysis,preferred_label,Thematic Analysis,preferred_label,39467871
Counseling,preferred_label,Counseling,preferred_label,39467871
excessive dna damage,semantic_types,excessive dna damage,semantic_types,39465258
pcd,preferred_label,pcd,preferred_label,39465258
panoptosis,preferred_label,panoptosis,preferred_label,39465258
pyroptosis,preferred_label,pyroptosis,preferred_label,39465258
apoptosis,preferred_label,apoptosis,preferred_label,39465258
necroptosis,preferred_label,necroptosis,preferred_label,39465258
z DNA binding protein 1,preferred_label,z DNA binding protein 1,preferred_label,39465258
endogenous retroviruses,preferred_label,endogenous retroviruses,preferred_label,39465258
chemotherapeutic drugs,preferred_label,chemotherapeutic drugs,preferred_label,39465258
tumor tissue,preferred_label,tumor tissue,preferred_label,39465258
colorectal cancer patients,preferred_label,colorectal cancer patients,preferred_label,39465258
dsrna,preferred_label,dsrna,preferred_label,39465258
normal colonic tissues,preferred_label,normal colonic tissues,preferred_label,39465258
tumor immunotherapy,preferred_label,tumor immunotherapy,preferred_label,39456702
cancer treatment,preferred_label,cancer treatment,preferred_label,39456702
immune cells,preferred_label,immune cells,preferred_label,39456702
suppressing checkpoints,preferred_label,suppressing checkpoints,preferred_label,39456702
tumor regression,preferred_label,tumor regression,preferred_label,39456702
tumor microenvironment,preferred_label,tumor microenvironment,preferred_label,39456702
effector immune cells,preferred_label,effector immune cells,preferred_label,39456702
inhibitory immune cells,preferred_label,inhibitory immune cells,preferred_label,39456702
immune related adverse events,preferred_label,immune related adverse events,preferred_label,39456702
inflammatory bowel disease,preferred_label,inflammatory bowel disease,preferred_label,39456702
tnf,preferred_label,tnf,preferred_label,39456702
ifn,preferred_label,ifn,preferred_label,39456702
immune checkpoint inhibitors induced colitis,preferred_label,immune checkpoint inhibitors induced colitis,preferred_label,39456702
epithelial cells,preferred_label,epithelial cells,preferred_label,39456702
breast cancer,class_id,breast cancer,class_id,39453820
chemotherapy,preferred_label,chemotherapy,preferred_label,39453820
surgical intervention,preferred_label,surgical intervention,preferred_label,39453820
radiation therapy,preferred_label,radiation therapy,preferred_label,39453820
hormone therapy,preferred_label,hormone therapy,preferred_label,39453820
biological therapy,preferred_label,biological therapy,preferred_label,39453820
plants,class_id,plants,class_id,39453820
natural products,preferred_label,natural products,preferred_label,39453820
anticancer drugs,preferred_label,anticancer drugs,preferred_label,39453820
bioactive compounds,preferred_label,bioactive compounds,preferred_label,39453820
immune checkpoint inhibitors,preferred_label,immune checkpoint inhibitors,preferred_label,39450164
immune related adverse events,preferred_label,immune related adverse events,preferred_label,39450164
endocrine toxicities,preferred_label,endocrine toxicities,preferred_label,39450164
diabetes mellitus,preferred_label,diabetes mellitus,preferred_label,39450164
thyroid dysfunction,preferred_label,thyroid dysfunction,preferred_label,39450164
patient,preferred_label,patient,preferred_label,39450164
sintilimab,preferred_label,sintilimab,preferred_label,39450164
cervical carcinoma,preferred_label,cervical carcinoma,preferred_label,39450164
diabetic ketoacidosis,preferred_label,diabetic ketoacidosis,preferred_label,39450164
hypothyroidism,preferred_label,hypothyroidism,preferred_label,39450164
insulin treatment,preferred_label,insulin treatment,preferred_label,39450164
chemotherapy,preferred_label,chemotherapy,preferred_label,39450164
spartalizumab,drug,spartalizumab,drug,39448966
canakinumab,drug,canakinumab,drug,39448966
gemcitabine,drug,gemcitabine,drug,39448966
cisplatin,drug,cisplatin,drug,39448966
pemetrexed,drug,pemetrexed,drug,39448966
paclitaxel,drug,paclitaxel,drug,39448966
non small cell lung cancer,disease,non small cell lung cancer,disease,39448966
posterior reversible encephalopathy syndrome,adverse event,posterior reversible encephalopathy syndrome,adverse event,39448966
hyponatremia,adverse event,hyponatremia,adverse event,39448966
neutropenic colitis,adverse event,neutropenic colitis,adverse event,39448966
clinicaltrials.gov,source,clinicaltrials.gov,source,39448966
triple negative breast carcinoma,class_id,triple negative breast carcinoma,class_id,39446014
chemotherapy,preferred_label,chemotherapy,preferred_label,39446014
monoclonal antibody drug conjugate sacituzumab govitecan,preferred_label,monoclonal antibody drug conjugate sacituzumab govitecan,preferred_label,39446014
elderly patient,preferred_label,elderly patient,preferred_label,39446014
triple negative breast carcinoma,class_id,triple negative breast carcinoma,class_id,39446012
sacituzumab govitecan,preferred_label,sacituzumab govitecan,preferred_label,39446012
elderly patients,preferred_label,elderly patients,preferred_label,39446012
metastatic breast cancer,preferred_label,metastatic breast cancer,preferred_label,39446012
luminal b,preferred_label,luminal b,preferred_label,39446012
hormonal and chemotherapeutic treatment,preferred_label,hormonal and chemotherapeutic treatment,preferred_label,39446012
g3 diarrhea,preferred_label,g3 diarrhea,preferred_label,39446012
quality of life,preferred_label,quality of life,preferred_label,39446012
partial response of the disease,preferred_label,partial response of the disease,preferred_label,39446012
inflammatory factors,semantic_types,inflammatory factors,semantic_types,39445010
coronavirus disease 19,semantic_types,coronavirus disease 19,semantic_types,39445010
covid 19,semantic_types,covid 19,semantic_types,39445010
acute respiratory syndrome coronavirus 2,semantic_types,acute respiratory syndrome coronavirus 2,semantic_types,39445010
sars cov 2,semantic_types,sars cov 2,semantic_types,39445010
drug exposure,semantic_types,drug exposure,semantic_types,39445010
mild infection,semantic_types,mild infection,semantic_types,39445010
plasma imatinib,semantic_types,plasma imatinib,semantic_types,39445010
norimatinib concentrations,semantic_types,norimatinib concentrations,semantic_types,39445010
patients,semantic_types,patients,semantic_types,39445010
gastrointestinal stromal tumor,semantic_types,gastrointestinal stromal tumor,semantic_types,39445010
imatinib metabolism,semantic_types,imatinib metabolism,semantic_types,39445010
transport,semantic_types,transport,semantic_types,39445010
cyp3a4,semantic_types,cyp3a4,semantic_types,39445010
cyp3a5,semantic_types,cyp3a5,semantic_types,39445010
abcb1,semantic_types,abcb1,semantic_types,39445010
abcg2,semantic_types,abcg2,semantic_types,39445010
infection,semantic_types,infection,semantic_types,39445010
side effects,semantic_types,side effects,semantic_types,39445010
case series,semantic_types,case series,semantic_types,39445010
acute myeloid leukemia,class_id,acute myeloid leukemia,class_id,39443599
stem cell,class_id,stem cell,class_id,39443599
malignancy,class_id,malignancy,class_id,39443599
chemotherapy,class_id,chemotherapy,class_id,39443599
cytarabine,class_id,cytarabine,class_id,39443599
daunorubicin,class_id,daunorubicin,class_id,39443599
therapy protocol,class_id,therapy protocol,class_id,39443599
hematopoietic system,class_id,hematopoietic system,class_id,39443599
adverse effects,class_id,adverse effects,class_id,39443599
blood cells,class_id,blood cells,class_id,39443599
stem cell niches,class_id,stem cell niches,class_id,39443599
mathematical model,class_id,mathematical model,class_id,39443599
clinical trial data,class_id,clinical trial data,class_id,39443599
cd34 cd38 aldh cells,class_id,cd34 cd38 aldh cells,class_id,39443599
complete remission,class_id,complete remission,class_id,39443599
g csf priming,class_id,g csf priming,class_id,39443599
salvage therapy,class_id,salvage therapy,class_id,39443599
minimal residual disease markers,class_id,minimal residual disease markers,class_id,39443599
immune check inhibitors,class_id,immune check inhibitors,class_id,39443053
biologic therapy,class_id,biologic therapy,class_id,39443053
cancer cells,class_id,cancer cells,class_id,39443053
toxicities,class_id,toxicities,class_id,39443053
immune related adverse events,class_id,immune related adverse events,class_id,39443053
endocrinopathies,class_id,endocrinopathies,class_id,39443053
organ system,class_id,organ system,class_id,39443053
preoperative assessment,class_id,preoperative assessment,class_id,39443053
liver cancer,disease,liver cancer,disease,39435040
low intensity ultrasound,treatment,low intensity ultrasound,treatment,39435040
nanomedicine delivery systems,drug delivery system,nanomedicine delivery systems,drug delivery system,39435040
folic acid modified nanoparticles,nanoparticles,folic acid modified nanoparticles,nanoparticles,39435040
fluorescent dye DIR,chemical compound,fluorescent dye DIR,chemical compound,39435040
liquid fluorocarbon PFP,chemical compound,liquid fluorocarbon PFP,chemical compound,39435040
crebanine polyethylene glycol polylactic acid copolymer nanoparticles,nanoparticles,crebanine polyethylene glycol polylactic acid copolymer nanoparticles,nanoparticles,39435040
ultrasonic irradiation,treatment,ultrasonic irradiation,treatment,39435040
H22 cells of mouse hepatoma,cell line,H22 cells of mouse hepatoma,cell line,39435040
small animal in vivo imaging system,imaging system,small animal in vivo imaging system,imaging system,39435040
hepatocellular carcinoma transplantation model,animal model,hepatocellular carcinoma transplantation model,animal model,39435040
liver,organ,liver,organ,39435040
kidney,organ,kidney,organ,39435040
sj gren s syndrome,preferred_label,sj gren s syndrome,preferred_label,39434886
immune checkpoint inhibitors,preferred_label,immune checkpoint inhibitors,preferred_label,39434886
autoimmune disease,semantic_types,autoimmune disease,semantic_types,39434886
breast cancer metastasis,preferred_label,breast cancer metastasis,preferred_label,39434886
atezolizumab,preferred_label,atezolizumab,preferred_label,39434886
nab paclitaxel,preferred_label,nab paclitaxel,preferred_label,39434886
prednisone,preferred_label,prednisone,preferred_label,39434886
pilocarpine,preferred_label,pilocarpine,preferred_label,39434886
hydroxychloroquine,preferred_label,hydroxychloroquine,preferred_label,39434886
neoadjuvant chemotherapy,preferred_label,neoadjuvant chemotherapy,preferred_label,39434886
surgery,preferred_label,surgery,preferred_label,39434886
radiotherapy,preferred_label,radiotherapy,preferred_label,39434886
lung nodules,preferred_label,lung nodules,preferred_label,39434886
lymph node involvement,preferred_label,lymph node involvement,preferred_label,39434886
multidisciplinary collaboration,preferred_label,multidisciplinary collaboration,preferred_label,39434886
cancer control,preferred_label,cancer control,preferred_label,39434886
patient quality of life,preferred_label,patient quality of life,preferred_label,39434886
adverse event,semantic_types,adverse event,semantic_types,39434886
rheumatological toxicity,preferred_label,rheumatological toxicity,preferred_label,39434886
irae,preferred_label,irae,preferred_label,39434886
neoadjuvant chemotherapy,preferred_label,neoadjuvant chemotherapy,preferred_label,39434886
immune checkpoint inhibitors,preferred_label,immune checkpoint inhibitors,preferred_label,39433998
chemotherapy,preferred_label,chemotherapy,preferred_label,39433998
endometrial cancer,preferred_label,endometrial cancer,preferred_label,39433998
network meta analysis,preferred_label,network meta analysis,preferred_label,39433998
patients,preferred_label,patients,preferred_label,39433998
phase i trials,preferred_label,phase i trials,preferred_label,39432880
oncology drug combinations,preferred_label,oncology drug combinations,preferred_label,39432880
toxicity adaptive lists design,preferred_label,toxicity adaptive lists design,preferred_label,39432880
tale,preferred_label,tale,preferred_label,39432880
dose escalation,preferred_label,dose escalation,preferred_label,39432880
de-escalation,preferred_label,de-escalation,preferred_label,39432880
toxicities,preferred_label,toxicities,preferred_label,39432880
maximum tolerated dose (MTD),preferred_label,maximum tolerated dose (MTD),preferred_label,39432880
Bayesian optimal interval design,preferred_label,Bayesian optimal interval design,preferred_label,39432880
copula,preferred_label,copula,preferred_label,39432880
product of independent beta probabilities escalation,preferred_label,product of independent beta probabilities escalation,preferred_label,39432880
continual reassessment method for partial ordering designs,preferred_label,continual reassessment method for partial ordering designs,preferred_label,39432880
overdosing patients,preferred_label,overdosing patients,preferred_label,39432880
patient safety,preferred_label,patient safety,preferred_label,39432880
r shiny application,preferred_label,r shiny application,preferred_label,39432880
r package,preferred_label,r package,preferred_label,39432880
relevant operating characteristics,preferred_label,relevant operating characteristics,preferred_label,39432880
risk of assigning highly toxic dose combinations,preferred_label,risk of assigning highly toxic dose combinations,preferred_label,39432880
mammary gland carcinoma,class_id,mammary gland carcinoma,class_id,39425456
hypoxia inducible factor 1alpha,preferred_label,hypoxia inducible factor 1alpha,preferred_label,39425456
fih 1,preferred_label,fih 1,preferred_label,39425456
chemical compounds,class_id,chemical compounds,class_id,39425456
bbap 8,preferred_label,bbap 8,preferred_label,39425456
mcf 7 cells,class_id,mcf 7 cells,class_id,39425456
7 12 dimethylbenz a anthracene,preferred_label,7 12 dimethylbenz a anthracene,preferred_label,39425456
wistar rats,class_id,wistar rats,class_id,39425456
glut 1,preferred_label,glut 1,preferred_label,39425456
pyrotinib,drug,pyrotinib,drug,39425028
metronomic oral etoposide,drug,metronomic oral etoposide,drug,39425028
her2 positive metastatic breast cancer,disease,her2 positive metastatic breast cancer,disease,39425028
trastuzumab,drug,trastuzumab,drug,39425028
nausea,adverse event,nausea,adverse event,39425028
vomiting,adverse event,vomiting,adverse event,39425028
diarrhea,adverse event,diarrhea,adverse event,39425028
anemia,adverse event,anemia,adverse event,39425028
peripheral neuropathy,adverse event,peripheral neuropathy,adverse event,39425028
cisplatin,drug,cisplatin,drug,39423903
nephrotoxicity,adverse event,nephrotoxicity,adverse event,39423903
ototoxicity,adverse event,ototoxicity,adverse event,39423903
neurotoxicity,adverse event,neurotoxicity,adverse event,39423903
myelosuppression,adverse event,myelosuppression,adverse event,39423903
oxidative stress,biological process,oxidative stress,biological process,39423903
inflammation,biological process,inflammation,biological process,39423903
dna damage,biological process,dna damage,biological process,39423903
cellular apoptosis,biological process,cellular apoptosis,biological process,39423903
kidney disease,disease,kidney disease,disease,39423903
hearing impairment,disease,hearing impairment,disease,39423903
neuropathy,disease,neuropathy,disease,39423903
liver function impairment,disease,liver function impairment,disease,39423903
comorbidities,medical condition,comorbidities,medical condition,39423903
therapeutic strategies,medical intervention,therapeutic strategies,medical intervention,39423903
cancer care,medical care,cancer care,medical care,39423903
chemotherapy,treated with drug,chemotherapy,treated with drug,39418176
platinum drugs,drug associated with AE,platinum drugs,drug associated with AE,39418176
hollow copper sulfide nanocubes,composed primarily of,hollow copper sulfide nanocubes,composed primarily of,39418176
pt iv drugs,drug associated with AE,pt iv drugs,drug associated with AE,39418176
glutathione,may prevent,glutathione,may prevent,39418176
reactive oxygen species,produces,reactive oxygen species,produces,39418176
large b cell lymphomas,class_id,large b cell lymphomas,class_id,39415456
anti cd19 chimeric antigen receptor,class_id,anti cd19 chimeric antigen receptor,class_id,39415456
Tisagenlecleucel,preferred_label,Tisagenlecleucel,preferred_label,39415456
Axicabtagene ciloleucel,preferred_label,Axicabtagene ciloleucel,preferred_label,39415456
University Hospitals Leuven,class_id,University Hospitals Leuven,class_id,39415456
cytokine release syndrome,preferred_label,cytokine release syndrome,preferred_label,39415456
immune effector cell associated neurotoxicity syndrome,preferred_label,immune effector cell associated neurotoxicity syndrome,preferred_label,39415456
cyclophosphamide,drug,cyclophosphamide,drug,39414093
arabinogalactan,polymer,arabinogalactan,polymer,39414093
ag,polymer,ag,polymer,39414093
as42 aptamers,oligonucleotide ligands,as42 aptamers,oligonucleotide ligands,39414093
erlich ascites cells,cell type,erlich ascites cells,cell type,39414093
ehrlich carcinoma,tumor model,ehrlich carcinoma,tumor model,39414093
tumor cells,cell type,tumor cells,cell type,39414093
mice,organism,mice,organism,39414093
cisplatin,drug,cisplatin,drug,39413735
gemcitabine,drug,gemcitabine,drug,39413735
toripalimab,drug,toripalimab,drug,39413735
nasopharyngeal carcinoma,disease,nasopharyngeal carcinoma,disease,39413735
patient,class_id,patient,class_id,39413735
adverse events,adverse event,adverse events,adverse event,39413735
headache,adverse event,headache,adverse event,39413735
nausea,adverse event,nausea,adverse event,39413735
brentuximab vedotin,drug,brentuximab vedotin,drug,39413375
classic hodgkin's lymphoma,disease,classic hodgkin's lymphoma,disease,39413375
adult patients,patient,adult patients,patient,39413375
pediatric patients,patient,pediatric patients,patient,39413375
radiation therapy,treatment,radiation therapy,treatment,39413375
programmed death 1 blockade,treatment,programmed death 1 blockade,treatment,39413375
doxorubicin,drug,doxorubicin,drug,39413375
vinblastine,drug,vinblastine,drug,39413375
dacarbazine,drug,dacarbazine,drug,39413375
nivolumab,drug,nivolumab,drug,39413375
progression free survival,outcome,progression free survival,outcome,39413375
disease progression,outcome,disease progression,outcome,39413375
Chemotherapy,may_treat,Chemotherapy,may_treat,39413318
Radiation,may_treat,Radiation,may_treat,39413318
Cutaneous Adverse Events,drug AE occurs in,Cutaneous Adverse Events,drug AE occurs in,39413318
Toxic Erythema of Chemotherapy,drug associated with AE,Toxic Erythema of Chemotherapy,drug associated with AE,39413318
Radiation Induced Dermatitis,drug associated with AE,Radiation Induced Dermatitis,drug associated with AE,39413318
Vitamin D Supplementation,may_prevent,Vitamin D Supplementation,may_prevent,39413318
Breast Cancer,has disease,Breast Cancer,has disease,39413318
Colorectal Cancer,has disease,Colorectal Cancer,has disease,39413318
Skin Toxicity,drug AE occurs in,Skin Toxicity,drug AE occurs in,39413318
Probiotics,preferred_label,Probiotics,preferred_label,39410854
Chemotherapy-induced diarrhea,preferred_label,Chemotherapy-induced diarrhea,preferred_label,39410854
Cancer patients,preferred_label,Cancer patients,preferred_label,39410854
Osmotic diarrhea,preferred_label,Osmotic diarrhea,preferred_label,39410854
Colonic crypts,preferred_label,Colonic crypts,preferred_label,39410854
Villi,preferred_label,Villi,preferred_label,39410854
Radiotherapy,preferred_label,Radiotherapy,preferred_label,39410854
Chemotherapy agents,preferred_label,Chemotherapy agents,preferred_label,39410854
Chloride absorption,preferred_label,Chloride absorption,preferred_label,39410854
Water release,preferred_label,Water release,preferred_label,39410854
Inflammatory pathways,preferred_label,Inflammatory pathways,preferred_label,39410854
Immunological responses,preferred_label,Immunological responses,preferred_label,39410854
Angiogenesis responses,preferred_label,Angiogenesis responses,preferred_label,39410854
Digestive enzymes metabolism,preferred_label,Digestive enzymes metabolism,preferred_label,39410854
Gut microbiota,preferred_label,Gut microbiota,preferred_label,39410854
Clinical research,preferred_label,Clinical research,preferred_label,39410854
immune checkpoint inhibitors,preferred_label,immune checkpoint inhibitors,preferred_label,39405648
immune related adverse events,preferred_label,immune related adverse events,preferred_label,39405648
adjuvant setting,preferred_label,adjuvant setting,preferred_label,39405648
therapy,preferred_label,therapy,preferred_label,39405648
real world data,preferred_label,real world data,preferred_label,39405648
patient population,preferred_label,patient population,preferred_label,39405648
clinical trial data,preferred_label,clinical trial data,preferred_label,39405648
irAEs,preferred_label,irAEs,preferred_label,39405648
anti-PD1 therapy,preferred_label,anti-PD1 therapy,preferred_label,39405648
nivolumab,preferred_label,nivolumab,preferred_label,39405648
resected stage III-IV melanoma,preferred_label,resected stage III-IV melanoma,preferred_label,39405648
national databases,preferred_label,national databases,preferred_label,39405648
immunotox database,preferred_label,immunotox database,preferred_label,39405648
Danish metastatic melanoma database,preferred_label,Danish metastatic melanoma database,preferred_label,39405648
organ systems,preferred_label,organ systems,preferred_label,39405648
CTCAE ver 5.0,preferred_label,CTCAE ver 5.0,preferred_label,39405648
toxicities,preferred_label,toxicities,preferred_label,39405648
progression-free survival,preferred_label,progression-free survival,preferred_label,39405648
overall survival,preferred_label,overall survival,preferred_label,39405648
seasonal pattern,preferred_label,seasonal pattern,preferred_label,39405648
melanoma relapse,preferred_label,melanoma relapse,preferred_label,39405648
gender,preferred_label,gender,preferred_label,39405648
age,preferred_label,age,preferred_label,39405648
incidence,preferred_label,incidence,preferred_label,39405648
Cytokines,preferred_label,Cytokines,preferred_label,39403930
Immune checkpoint inhibition,preferred_label,Immune checkpoint inhibition,preferred_label,39403930
T helper cells,preferred_label,T helper cells,preferred_label,39403930
Solid tumors,preferred_label,Solid tumors,preferred_label,39403930
Autoimmune disorders,preferred_label,Autoimmune disorders,preferred_label,39403930
IL-5,preferred_label,IL-5,preferred_label,39403930
IL-6,preferred_label,IL-6,preferred_label,39403930
IL-17F,preferred_label,IL-17F,preferred_label,39403930
TNF-alpha,preferred_label,TNF-alpha,preferred_label,39403930
Objective response rate,preferred_label,Objective response rate,preferred_label,39403930
Cancer-specific mortality,preferred_label,Cancer-specific mortality,preferred_label,39403930
All-cause mortality,preferred_label,All-cause mortality,preferred_label,39403930
IL-6 blockade,preferred_label,IL-6 blockade,preferred_label,39403930
neoadjuvant endocrine therapy,preferred_label,neoadjuvant endocrine therapy,preferred_label,39384801
chemotherapy,preferred_label,chemotherapy,preferred_label,39384801
angiogenesis,preferred_label,angiogenesis,preferred_label,39384801
sunitinib,preferred_label,sunitinib,preferred_label,39384801
exemestane,preferred_label,exemestane,preferred_label,39384801
breast cancer,preferred_label,breast cancer,preferred_label,39384801
postmenopausal women,preferred_label,postmenopausal women,preferred_label,39384801
vegfr 2,preferred_label,vegfr 2,preferred_label,39384801
esr1,preferred_label,esr1,preferred_label,39384801
pgr,preferred_label,pgr,preferred_label,39384801
nat1,preferred_label,nat1,preferred_label,39384801
egfr,preferred_label,egfr,preferred_label,39384801
myc,preferred_label,myc,preferred_label,39384801
sfrp1,preferred_label,sfrp1,preferred_label,39384801
foxc1,preferred_label,foxc1,preferred_label,39384801
Luminal A subtype,preferred_label,Luminal A subtype,preferred_label,39384801
cancer treatment,treated with drug,cancer treatment,treated with drug,39384243
high dose chemotherapy,treated with drug,high dose chemotherapy,treated with drug,39384243
mucosal barrier,composed primarily of,mucosal barrier,composed primarily of,39384243
gastrointestinal tract,composed primarily of,gastrointestinal tract,composed primarily of,39384243
gi mucositis,has disease,gi mucositis,has disease,39384243
glucagon like peptide 1 (glp 1),drug associated with AE,glucagon like peptide 1 (glp 1),drug associated with AE,39384243
blood glucose,bearer of,blood glucose,bearer of,39384243
gut epithelial cells,composed primarily of,gut epithelial cells,composed primarily of,39384243
toxicities,adverse event occurs in,toxicities,adverse event occurs in,39384243
haematopoietic stem cell transplantation (hsct),may_treat,haematopoietic stem cell transplantation (hsct),may_treat,39384243
glp 1 receptor agonist (glp 1ra),drug associated with AE,glp 1 receptor agonist (glp 1ra),drug associated with AE,39384243
lymphoma,has disease,lymphoma,has disease,39384243
autologous hsct (auto hsct),may_treat,autologous hsct (auto hsct),may_treat,39384243
clinical study,example of usage,clinical study,example of usage,39384243
patients,occurs in patient treated with drug,patients,occurs in patient treated with drug,39384243
primary endpoint,realized in,primary endpoint,realized in,39384243
secondary endpoints,realized in,secondary endpoints,realized in,39384243
safety,protects,safety,protects,39384243
perioperative immunotherapy,semantic_types,perioperative immunotherapy,semantic_types,39382658
resectable non small cell lung cancer (NSCLC),semantic_types,resectable non small cell lung cancer (NSCLC),semantic_types,39382658
immune checkpoint inhibitors,semantic_types,immune checkpoint inhibitors,semantic_types,39382658
chemotherapy,semantic_types,chemotherapy,semantic_types,39382658
systematic review,semantic_types,systematic review,semantic_types,39382658
Bayesian network meta analysis,semantic_types,Bayesian network meta analysis,semantic_types,39382658
neoadjuvant plus adjuvant immunotherapy,semantic_types,neoadjuvant plus adjuvant immunotherapy,semantic_types,39382658
neoadjuvant immunotherapy,semantic_types,neoadjuvant immunotherapy,semantic_types,39382658
event-free survival (EFS),semantic_types,event-free survival (EFS),semantic_types,39382658
overall survival (OS),semantic_types,overall survival (OS),semantic_types,39382658
treatment-related adverse events (TRAEs),semantic_types,treatment-related adverse events (TRAEs),semantic_types,39382658
PD-L1,semantic_types,PD-L1,semantic_types,39382658
toxicity,semantic_types,toxicity,semantic_types,39382658
COVID-19 infection,semantic_types,COVID-19 infection,semantic_types,39377592
PD-1 PD-L1 inhibitor therapy,semantic_types,PD-1 PD-L1 inhibitor therapy,semantic_types,39377592
cancer patients,semantic_types,cancer patients,semantic_types,39377592
immune related adverse events (IRAEs),semantic_types,immune related adverse events (IRAEs),semantic_types,39377592
axitinib,drug,axitinib,drug,39377544
vascular endothelial growth factor receptors,protein,vascular endothelial growth factor receptors,protein,39377544
renal cell carcinoma,disease,renal cell carcinoma,disease,39377544
glioblastoma,disease,glioblastoma,disease,39377544
glioma stem cells,cell type,glioma stem cells,cell type,39377544
n-acetyl-l-cysteine,drug,n-acetyl-l-cysteine,drug,39377544
liver vasculature,anatomy,liver vasculature,anatomy,39377544
cannabis extract,preferred_label,cannabis extract,preferred_label,39375818
nanoemulsion,preferred_label,nanoemulsion,preferred_label,39375818
9-tetrahydrocannabinol (THC),preferred_label,9-tetrahydrocannabinol (THC),preferred_label,39375818
cannabidiol (CBD),preferred_label,cannabidiol (CBD),preferred_label,39375818
animal model of glioblastoma,preferred_label,animal model of glioblastoma,preferred_label,39375818
C6 tumor model in rats,preferred_label,C6 tumor model in rats,preferred_label,39375818
hemocompatibility factors,preferred_label,hemocompatibility factors,preferred_label,39375818
MRI,preferred_label,MRI,preferred_label,39375818
brain glioblastoma tumor progression,preferred_label,brain glioblastoma tumor progression,preferred_label,39375818
anlotinib,drug,anlotinib,drug,39375657
docetaxel,drug,docetaxel,drug,39375657
epirubicin,drug,epirubicin,drug,39375657
cyclophosphamide,drug,cyclophosphamide,drug,39375657
locally advanced tnbc,disease,locally advanced tnbc,disease,39375657
neoadjuvant chemotherapy regimen,treatment,neoadjuvant chemotherapy regimen,treatment,39375657
patients,patient,patients,patient,39375657
surgery,procedure,surgery,procedure,39375657
adverse events,adverse event,adverse events,adverse event,39375657
grade 3 or 4 adverse events,adverse event,grade 3 or 4 adverse events,adverse event,39375657
neutropenia,adverse event,neutropenia,adverse event,39375657
palmar plantar erythrodysesthesia syndrome,adverse event,palmar plantar erythrodysesthesia syndrome,adverse event,39375657
combination regimen,treatment,combination regimen,treatment,39375657
metastatic pancreatic ductal adenocarcinoma,class_id,metastatic pancreatic ductal adenocarcinoma,class_id,39369582
pharmacological ascorbate,preferred_label,pharmacological ascorbate,preferred_label,39369582
gemcitabine,preferred_label,gemcitabine,preferred_label,39369582
nab paclitaxel,preferred_label,nab paclitaxel,preferred_label,39369582
immune checkpoint inhibitors,drug,immune checkpoint inhibitors,drug,39368044
older adults,class_id,older adults,class_id,39368044
immune related adverse events,adverse event,immune related adverse events,adverse event,39368044
immune ageing,class_id,immune ageing,class_id,39368044
corticosteroids,drug,corticosteroids,drug,39368044
frailty,class_id,frailty,class_id,39368044
anaplastic meningiomas,class_id,anaplastic meningiomas,class_id,39358739
who grade 3 tumors,preferred_label,who grade 3 tumors,preferred_label,39358739
recurrent anaplastic meningioma,preferred_label,recurrent anaplastic meningioma,preferred_label,39358739
re irradiation,preferred_label,re irradiation,preferred_label,39358739
surgery,preferred_label,surgery,preferred_label,39358739
radiation,preferred_label,radiation,preferred_label,39358739
local control,preferred_label,local control,preferred_label,39358739
progression free survival,preferred_label,progression free survival,preferred_label,39358739
treatment related adverse events,preferred_label,treatment related adverse events,preferred_label,39358739
bevacizumab,preferred_label,bevacizumab,preferred_label,39358739
radiation necrosis,preferred_label,radiation necrosis,preferred_label,39358739
cdkn2a homozygote deletion,preferred_label,cdkn2a homozygote deletion,preferred_label,39358739
icc,preferred_label,icc,preferred_label,39358645
lenvatinib plus toripalimab,preferred_label,lenvatinib plus toripalimab,preferred_label,39358645
chemo,preferred_label,chemo,preferred_label,39358645
pd 1 antibody,preferred_label,pd 1 antibody,preferred_label,39358645
ca19 9 levels,preferred_label,ca19 9 levels,preferred_label,39358645
idh1 mutations,preferred_label,idh1 mutations,preferred_label,39358645
akt,class_id,akt,class_id,39353238
cell survival,preferred_label,cell survival,preferred_label,39353238
proliferation,preferred_label,proliferation,preferred_label,39353238
metabolism,preferred_label,metabolism,preferred_label,39353238
small molecule akt inhibitors,preferred_label,small molecule akt inhibitors,preferred_label,39353238
cancer,preferred_label,cancer,preferred_label,39353238
inflammatory diseases,preferred_label,inflammatory diseases,preferred_label,39353238
atp competitive and allosteric modulators,preferred_label,atp competitive and allosteric modulators,preferred_label,39353238
specificity,preferred_label,specificity,preferred_label,39353238
bioavailability,preferred_label,bioavailability,preferred_label,39353238
toxicity,preferred_label,toxicity,preferred_label,39353238
pharmacokinetic properties,preferred_label,pharmacokinetic properties,preferred_label,39353238
structural modifications,preferred_label,structural modifications,preferred_label,39353238
prodrugs,preferred_label,prodrugs,preferred_label,39353238
efficacy,preferred_label,efficacy,preferred_label,39353238
safety profile,preferred_label,safety profile,preferred_label,39353238
therapeutic window,preferred_label,therapeutic window,preferred_label,39353238
adverse effects,preferred_label,adverse effects,preferred_label,39353238
clinical success,preferred_label,clinical success,preferred_label,39353238
refinement,preferred_label,refinement,preferred_label,39353238
cisplatin,drug,cisplatin,drug,39353216
gemcitabine,drug,gemcitabine,drug,39353216
biliary tract cancer,disease,biliary tract cancer,disease,39353216
nivolumab,drug,nivolumab,drug,39353216
lenvatinib,drug,lenvatinib,drug,39353216
myocarditis,adverse event,myocarditis,adverse event,39353216
hypertension,adverse event,hypertension,adverse event,39353216
biliary tract infection,adverse event,biliary tract infection,adverse event,39353216
rash,adverse event,rash,adverse event,39353216
hypothyroidism,adverse event,hypothyroidism,adverse event,39353216
melanoma,class_id,melanoma,class_id,39353049
nitric oxide,class_id,nitric oxide,class_id,39353049
immunotherapies,class_id,immunotherapies,class_id,39353049
skin cancer,class_id,skin cancer,class_id,39353049
drug resistance,class_id,drug resistance,class_id,39353049
adverse side effects,class_id,adverse side effects,class_id,39353049
chemical no donors,class_id,chemical no donors,class_id,39353049
macromolecular no donor systems,class_id,macromolecular no donor systems,class_id,39353049
skin permeation,class_id,skin permeation,class_id,39353049
toxicity,class_id,toxicity,class_id,39353049
melanoma cells,class_id,melanoma cells,class_id,39353049
healthy cells,class_id,healthy cells,class_id,39353049
in vitro model,class_id,in vitro model,class_id,39353049
older adults,class_id,older adults,class_id,39357051
cancer treatment,class_id,cancer treatment,class_id,39357051
toxicity,class_id,toxicity,class_id,39357051
adverse events,class_id,adverse events,class_id,39357051
chemotherapy induced nausea and vomiting (CINV),class_id,chemotherapy induced nausea and vomiting (CINV),class_id,39357051
serious game (Managing at Home - MAH),class_id,serious game (Managing at Home - MAH),class_id,39357051
self management strategies,class_id,self management strategies,class_id,39357051
intervention group,class_id,intervention group,class_id,39357051
control group,class_id,control group,class_id,39357051
baseline,class_id,baseline,class_id,39357051
treatment cycle,class_id,treatment cycle,class_id,39357051
English,class_id,English,class_id,39357051
telephone,class_id,telephone,class_id,39357051
cancer related chemotherapy,class_id,cancer related chemotherapy,class_id,39357051
emetic potential,class_id,emetic potential,class_id,39357051
visual impairment,class_id,visual impairment,class_id,39357051
hearing impairment,class_id,hearing impairment,class_id,39357051
p glycoprotein,class_id,p glycoprotein,class_id,39356462
breast cancer resistance protein,class_id,breast cancer resistance protein,class_id,39356462
testis,class_id,testis,class_id,39356462
reproductive toxicity in males,class_id,reproductive toxicity in males,class_id,39356462
spermatogenesis,class_id,spermatogenesis,class_id,39356462
anti tumor agents,class_id,anti tumor agents,class_id,39356462
blood testis barrier,class_id,blood testis barrier,class_id,39356462
exogenous compounds,class_id,exogenous compounds,class_id,39356462
high dose methotrexate,drug,high dose methotrexate,drug,39356310
delayed methotrexate elimination,adverse event,delayed methotrexate elimination,adverse event,39356310
renal dysfunction,adverse event outcome,renal dysfunction,adverse event outcome,39356310
glucarpidase,drug,glucarpidase,drug,39356310
hyperhydration,supportive measure,hyperhydration,supportive measure,39356310
urine alkalinization,supportive measure,urine alkalinization,supportive measure,39356310
leucovorin rescue,treatment,leucovorin rescue,treatment,39356310
intensified hydration,treatment,intensified hydration,treatment,39356310
5 arylaminouracil derivatives,class_id,5 arylaminouracil derivatives,class_id,39355889
hiv 1,preferred_label,hiv 1,preferred_label,39355889
herpesviruses,preferred_label,herpesviruses,preferred_label,39355889
mycobacteria,preferred_label,mycobacteria,preferred_label,39355889
leukemia,preferred_label,leukemia,preferred_label,39355889
neuroblastoma,preferred_label,neuroblastoma,preferred_label,39355889
glial brain tumors,preferred_label,glial brain tumors,preferred_label,39355889
5 aminouracils,class_id,5 aminouracils,class_id,39355889
5 norcabocyclic and ribo derivatives,class_id,5 norcabocyclic and ribo derivatives,class_id,39355889
cytotoxicity,preferred_label,cytotoxicity,preferred_label,39355889
neuroblastoma cell lines,class_id,neuroblastoma cell lines,class_id,39355889
sh sy5y,preferred_label,sh sy5y,preferred_label,39355889
imr 32,preferred_label,imr 32,preferred_label,39355889
k 562 lymphoblastic cells,class_id,k 562 lymphoblastic cells,class_id,39355889
hl 60 promyeoloblastic cells,class_id,hl 60 promyeoloblastic cells,class_id,39355889
glioblastoma multiforme,preferred_label,glioblastoma multiforme,preferred_label,39355889
gbm5522,preferred_label,gbm5522,preferred_label,39355889
gbm6138,preferred_label,gbm6138,preferred_label,39355889
isopropylphenylamine uracil,class_id,isopropylphenylamine uracil,class_id,39355889
tert butylphenylamine uracil,class_id,tert butylphenylamine uracil,class_id,39355889
half maximal inhibitory concentrations (IC50),preferred_label,half maximal inhibitory concentrations (IC50),preferred_label,39355889
antitumor activity,preferred_label,antitumor activity,preferred_label,39355889
fluoropyrimidines,drug,fluoropyrimidines,drug,39350200
solid tumors,disease,solid tumors,disease,39350200
dihydropyrimidine dehydrogenase,enzyme,dihydropyrimidine dehydrogenase,enzyme,39350200
dpyd gene,gene,dpyd gene,gene,39350200
dpyd deficiency,genetic condition,dpyd deficiency,genetic condition,39350200
pyrimidine metabolism,metabolic process,pyrimidine metabolism,metabolic process,39350200
toxicity,adverse event outcome,toxicity,adverse event outcome,39350200
cancer patients,patient,cancer patients,patient,39350200
5-fluorouracil,drug,5-fluorouracil,drug,39350200
dpd deficiency,genetic condition,dpd deficiency,genetic condition,39350200
treatment-related mortality,adverse event outcome,treatment-related mortality,adverse event outcome,39350200
meta-analysis,study,meta-analysis,study,39350200
dpyd variants,genetic mutation,dpyd variants,genetic mutation,39350200
immune checkpoint inhibitors,preferred_label,immune checkpoint inhibitors,preferred_label,39348984
metastatic urothelial carcinoma,preferred_label,metastatic urothelial carcinoma,preferred_label,39348984
immune related adverse events,preferred_label,immune related adverse events,preferred_label,39348984
baseline neutrophil to lymphocyte ratio,preferred_label,baseline neutrophil to lymphocyte ratio,preferred_label,39348984
systemic immune inflammation index,preferred_label,systemic immune inflammation index,preferred_label,39348984
platelet to lymphocyte ratio,preferred_label,platelet to lymphocyte ratio,preferred_label,39348984
patients,preferred_label,patients,preferred_label,39348984
anti pd1,preferred_label,anti pd1,preferred_label,39348984
anti pd l1,preferred_label,anti pd l1,preferred_label,39348984
jcog1008,class_id,jcog1008,class_id,39348265
cisplatin,preferred_label,cisplatin,preferred_label,39348265
acute kidney injury,preferred_label,acute kidney injury,preferred_label,39348265
chemoradiotherapy,preferred_label,chemoradiotherapy,preferred_label,39348265
head and neck cancer,preferred_label,head and neck cancer,preferred_label,39348265
Desmoid tumors,class_id,Desmoid tumors,class_id,39343510
Ipilimumab and nivolumab,drug,Ipilimumab and nivolumab,drug,39343510
SWOG S1609,class_id,SWOG S1609,class_id,39343510
DART trial,class_id,DART trial,class_id,39343510
cervical cancer,preferred_label,cervical cancer,preferred_label,39342591
brachytherapy,preferred_label,brachytherapy,preferred_label,39342591
cisplatin,preferred_label,cisplatin,preferred_label,39342591
chemoradiation,preferred_label,chemoradiation,preferred_label,39342591
ebrt,preferred_label,ebrt,preferred_label,39342591
clinical trial,preferred_label,clinical trial,preferred_label,39342591
Palbociclib,drug,Palbociclib,drug,39342581
Ribociclib,drug,Ribociclib,drug,39342581
Breast Cancer,disease,Breast Cancer,disease,39342581
Fulvestrant,drug,Fulvestrant,drug,39342581
Goserelin,drug,Goserelin,drug,39342581
EORTC Quality of Life Questionnaire,assessment tool,EORTC Quality of Life Questionnaire,assessment tool,39342581
CTCAE v5.0,assessment tool,CTCAE v5.0,assessment tool,39342581
colorectal cancer,class_id,colorectal cancer,class_id,39339648
5-fluorouracil,preferred_label,5-fluorouracil,preferred_label,39339648
taurine,preferred_label,taurine,preferred_label,39339648
chemotherapeutic agent,preferred_label,chemotherapeutic agent,preferred_label,39339648
adverse effects,preferred_label,adverse effects,preferred_label,39339648
adenocarcinoma,preferred_label,adenocarcinoma,preferred_label,39339648
"1,2-dimethylhydrazine",preferred_label,"1,2-dimethylhydrazine",preferred_label,39339648
rats,preferred_label,rats,preferred_label,39339648
colon tissues,preferred_label,colon tissues,preferred_label,39339648
genes,preferred_label,genes,preferred_label,39339648
APC,preferred_label,APC,preferred_label,39339648
catenin,preferred_label,catenin,preferred_label,39339648
mitotic index,preferred_label,mitotic index,preferred_label,39339648
dysplasia,preferred_label,dysplasia,preferred_label,39339648
hepatocellular carcinoma,class_id,hepatocellular carcinoma,class_id,39339402
sorafenib,preferred_label,sorafenib,preferred_label,39339402
lenvatinib,preferred_label,lenvatinib,preferred_label,39339402
nanotechnology,preferred_label,nanotechnology,preferred_label,39339402
nanocarriers,preferred_label,nanocarriers,preferred_label,39339402
targeted inhibitors,preferred_label,targeted inhibitors,preferred_label,39339402
chemotherapeutic agents,preferred_label,chemotherapeutic agents,preferred_label,39339402
gene therapy,preferred_label,gene therapy,preferred_label,39339402
phototherapy,preferred_label,phototherapy,preferred_label,39339402
immunotherapy,preferred_label,immunotherapy,preferred_label,39339402
combinatorial treatments,preferred_label,combinatorial treatments,preferred_label,39339402
immune checkpoint inhibitors,drug,immune checkpoint inhibitors,drug,39334098
proton pump inhibitors,drug,proton pump inhibitors,drug,39334098
US Food and Drug Administration Adverse Event Reporting System,system,US Food and Drug Administration Adverse Event Reporting System,system,39334098
"congenital, familial, and genetic disorders",disease,"congenital, familial, and genetic disorders",disease,39334098
hepatobiliary disorders,disease,hepatobiliary disorders,disease,39334098
metabolism and nutrition disorders,disease,metabolism and nutrition disorders,disease,39334098
skin and subcutaneous tissue disorders,disease,skin and subcutaneous tissue disorders,disease,39334098
programmed death 1,protein,programmed death 1,protein,39334098
programmed death ligand 1,protein,programmed death ligand 1,protein,39334098
cytotoxic t lymphocyte antigen 4,protein,cytotoxic t lymphocyte antigen 4,protein,39334098
standardized MedDRA query system organ class toxicities,system,standardized MedDRA query system organ class toxicities,system,39334098
lenvatinib,drug,lenvatinib,drug,39333610
hepatocellular carcinoma,disease,hepatocellular carcinoma,disease,39333610
muscle loss,clinical finding,muscle loss,clinical finding,39333610
patients,patient group,patients,patient group,39333610
Germany,location,Germany,location,39333610
antibody drug conjugate,drug,antibody drug conjugate,drug,39333227
immune checkpoint inhibitors,drug,immune checkpoint inhibitors,drug,39333227
cancer,disease,cancer,disease,39333227
efficacy,outcome measure,efficacy,outcome measure,39333227
safety,outcome measure,safety,outcome measure,39333227
combination therapy,treatment,combination therapy,treatment,39333227
adverse effects,outcome measure,adverse effects,outcome measure,39333227
Hodgkin lymphoma,disease,Hodgkin lymphoma,disease,39333227
Non-Hodgkin lymphoma,disease,Non-Hodgkin lymphoma,disease,39333227
peripheral neuropathy,adverse event,peripheral neuropathy,adverse event,39333227
skin issues,adverse event,skin issues,adverse event,39333227
digestive system problems,adverse event,digestive system problems,adverse event,39333227
egfr targeted therapies,drug,egfr targeted therapies,drug,39330834
urokinase type plasminogen activator receptor (upar),protein,urokinase type plasminogen activator receptor (upar),protein,39330834
recombinant ebat,drug,recombinant ebat,drug,39330834
cytokines egf and upa,protein,cytokines egf and upa,protein,39330834
truncated pseudomonas toxin,toxin,truncated pseudomonas toxin,toxin,39330834
tumors,tissue,tumors,tissue,39330834
vasculature,tissue,vasculature,tissue,39330834
tumor microenvironment,biological environment,tumor microenvironment,biological environment,39330834
mice,animal model,mice,animal model,39330834
dogs,animal model,dogs,animal model,39330834
sarcoma,disease,sarcoma,disease,39330834
liver,organ,liver,organ,39330834
portal biliary hyperplasia,pathological process,portal biliary hyperplasia,pathological process,39330834
oval cell proliferation,pathological process,oval cell proliferation,pathological process,39330834
lymphoplasmacytic inflammation,pathological process,lymphoplasmacytic inflammation,pathological process,39330834
periportal hepatocellular microvesicular change,pathological process,periportal hepatocellular microvesicular change,pathological process,39330834
hemorrhage,pathological process,hemorrhage,pathological process,39330834
necrosis,pathological process,necrosis,pathological process,39330834
apoptosis,pathological process,apoptosis,pathological process,39330834
surufatinib,drug,surufatinib,drug,39327433
toripalimab,drug,toripalimab,drug,39327433
etoposide,drug,etoposide,drug,39327433
cisplatin,drug,cisplatin,drug,39327433
small cell lung cancer,disease,small cell lung cancer,disease,39327433
progression free survival,outcome,progression free survival,outcome,39327433
objective response rate,outcome,objective response rate,outcome,39327433
disease control rate,outcome,disease control rate,outcome,39327433
overall survival,outcome,overall survival,outcome,39327433
adverse events,outcome,adverse events,outcome,39327433
chromosomal aberrations,preferred_label,chromosomal aberrations,preferred_label,39326941
bleomycin,preferred_label,bleomycin,preferred_label,39326941
human lymphoblastoid cells,preferred_label,human lymphoblastoid cells,preferred_label,39326941
Epstein Barr virus,preferred_label,Epstein Barr virus,preferred_label,39326941
nqbio 06,class_id,nqbio 06,class_id,39326936
nqbio 21,class_id,nqbio 21,class_id,39326936
carboline alkaloids,preferred_label,carboline alkaloids,preferred_label,39326936
ovarian cancer cell line tov 21 g,preferred_label,ovarian cancer cell line tov 21 g,preferred_label,39326936
mda mb 231 breast cancer cells,preferred_label,mda mb 231 breast cancer cells,preferred_label,39326936
chromosomal breaks,preferred_label,chromosomal breaks,preferred_label,39326936
micronucleus assay,preferred_label,micronucleus assay,preferred_label,39326936
lipinski s rules,preferred_label,lipinski s rules,preferred_label,39326936
intestinal absorption,preferred_label,intestinal absorption,preferred_label,39326936
p glycoprotein,preferred_label,p glycoprotein,preferred_label,39326936
amivantamab,drug,amivantamab,drug,39324708
epidermal growth factor receptor,protein,epidermal growth factor receptor,protein,39324708
met,protein,met,protein,39324708
non small cell lung cancer,disease,non small cell lung cancer,disease,39324708
cutaneous toxicities,adverse event,cutaneous toxicities,adverse event,39324708
rash,adverse event,rash,adverse event,39324708
paronychia,adverse event,paronychia,adverse event,39324708
dermatitis acneiform,adverse event,dermatitis acneiform,adverse event,39324708
nurses,healthcare provider,nurses,healthcare provider,39324708
advanced practice providers,healthcare provider,advanced practice providers,healthcare provider,39324708
physicians,healthcare provider,physicians,healthcare provider,39324708
immune checkpoint inhibitors,preferred_label,immune checkpoint inhibitors,preferred_label,39320566
patients,preferred_label,patients,preferred_label,39320566
caregivers,preferred_label,caregivers,preferred_label,39320566
non small cell lung cancer,preferred_label,non small cell lung cancer,preferred_label,39320566
melanoma,preferred_label,melanoma,preferred_label,39320566
side effects,preferred_label,side effects,preferred_label,39320566
oncologist,preferred_label,oncologist,preferred_label,39320566
tyrosine kinase inhibitors,drug,tyrosine kinase inhibitors,drug,39318033
cardiac side effects,adverse event,cardiac side effects,adverse event,39318033
extracellular vesicles,class_id,extracellular vesicles,class_id,39316382
bleb nanovesicles,class_id,bleb nanovesicles,class_id,39316382
human fc receptor I (hCD64),class_id,human fc receptor I (hCD64),class_id,39316382
monomeric IgG,class_id,monomeric IgG,class_id,39316382
prostate cancer,class_id,prostate cancer,class_id,39316382
prostate specific membrane antigen (PSMA),class_id,prostate specific membrane antigen (PSMA),class_id,39316382
osteosarcoma,class_id,osteosarcoma,class_id,39315544
gemcitabine and docetaxel combination chemotherapy,preferred_label,gemcitabine and docetaxel combination chemotherapy,preferred_label,39315544
gemdox,synonyms,gemdox,synonyms,39315544
toxicities,preferred_label,toxicities,preferred_label,39315544
cell lines,preferred_label,cell lines,preferred_label,39315544
clinical trials,preferred_label,clinical trials,preferred_label,39315544
immune checkpoint inhibitors,preferred_label,immune checkpoint inhibitors,preferred_label,39311981
anti cytotoxic t lymphocyte associated protein 4,preferred_label,anti cytotoxic t lymphocyte associated protein 4,preferred_label,39311981
anti programmed cell death 1 programmed cell death ligand 1,preferred_label,anti programmed cell death 1 programmed cell death ligand 1,preferred_label,39311981
gastrointestinal immune related adverse events,preferred_label,gastrointestinal immune related adverse events,preferred_label,39311981
diarrhea,preferred_label,diarrhea,preferred_label,39311981
colitis,preferred_label,colitis,preferred_label,39311981
imdc,preferred_label,imdc,preferred_label,39311981
corticosteroids,preferred_label,corticosteroids,preferred_label,39311981
infliximab,preferred_label,infliximab,preferred_label,39311981
vedolizumab,preferred_label,vedolizumab,preferred_label,39311981
microbiota transplantation,preferred_label,microbiota transplantation,preferred_label,39311981
cytokines,preferred_label,cytokines,preferred_label,39311981
lymphocyte replication inhibitors,preferred_label,lymphocyte replication inhibitors,preferred_label,39311981
nanotechnology,class_id,nanotechnology,class_id,39308042
cancer treatments,preferred_label,cancer treatments,preferred_label,39308042
chemotherapy resistance,preferred_label,chemotherapy resistance,preferred_label,39308042
side effects,preferred_label,side effects,preferred_label,39308042
silver nanoparticles,preferred_label,silver nanoparticles,preferred_label,39308042
antimicrobial properties,preferred_label,antimicrobial properties,preferred_label,39308042
antiproliferative properties,preferred_label,antiproliferative properties,preferred_label,39308042
nanotoxicological assessment,preferred_label,nanotoxicological assessment,preferred_label,39308042
combination index,preferred_label,combination index,preferred_label,39308042
cytotoxic effect,preferred_label,cytotoxic effect,preferred_label,39308042
antiproliferative effect,preferred_label,antiproliferative effect,preferred_label,39308042
cell migration,preferred_label,cell migration,preferred_label,39308042
reactive oxygen species production,preferred_label,reactive oxygen species production,preferred_label,39308042
genotoxic effect,preferred_label,genotoxic effect,preferred_label,39308042
proapoptotic gene expression,preferred_label,proapoptotic gene expression,preferred_label,39308042
oxidative stress gene expression,preferred_label,oxidative stress gene expression,preferred_label,39308042
internalization,preferred_label,internalization,preferred_label,39308042
breast cancer cells,preferred_label,breast cancer cells,preferred_label,39308042
chemotherapeutic agents,preferred_label,chemotherapeutic agents,preferred_label,39308042
oncology therapy,preferred_label,oncology therapy,preferred_label,39308042
selinexor,drug,selinexor,drug,39307725
venetoclax,drug,venetoclax,drug,39307725
azactitidine,drug,azactitidine,drug,39307725
acute myeloid leukemia,disease,acute myeloid leukemia,disease,39307725
patients,class_id,patients,class_id,39307725
complete remission,adverse event outcome,complete remission,adverse event outcome,39307725
hematological toxicity,adverse event outcome,hematological toxicity,adverse event outcome,39307725
malignant tumors,class_id,malignant tumors,class_id,39307710
cancer patients,class_id,cancer patients,class_id,39307710
cardiovascular toxicity,class_id,cardiovascular toxicity,class_id,39307710
cardiac biomarkers,class_id,cardiac biomarkers,class_id,39307710
cardio oncology,class_id,cardio oncology,class_id,39307710
cardiovascular diseases,class_id,cardiovascular diseases,class_id,39307710
consensus,class_id,consensus,class_id,39307710
immune checkpoint inhibitors,drug,immune checkpoint inhibitors,drug,39307038
esophageal squamous cell carcinoma,disease,esophageal squamous cell carcinoma,disease,39307038
camrelizumab,drug,camrelizumab,drug,39307038
apatinib,drug,apatinib,drug,39307038
patients,class_id,patients,class_id,39307038
disease progression,adverse event outcome,disease progression,adverse event outcome,39307038
sacituzumab govitecan,drug,sacituzumab govitecan,drug,39302614
trop 2,protein,trop 2,protein,39302614
metastatic triple negative breast cancer,disease,metastatic triple negative breast cancer,disease,39302614
ascent study,clinical trial,ascent study,clinical trial,39302614
Japanese patients,population,Japanese patients,population,39302614
solid tumors,disease,solid tumors,disease,39302614
phase 1,clinical trial phase,phase 1,clinical trial phase,39302614
phase 2,clinical trial phase,phase 2,clinical trial phase,39302614
objective response rate,clinical parameter,objective response rate,clinical parameter,39302614
progression free survival,clinical parameter,progression free survival,clinical parameter,39302614
overall survival,clinical parameter,overall survival,clinical parameter,39302614
drug induced pneumonitis,adverse event,drug induced pneumonitis,adverse event,39302574
lung cancer systemic therapy,treatment,lung cancer systemic therapy,treatment,39302574
immunotherapy,treatment,immunotherapy,treatment,39302574
immune checkpoint inhibitors,drug,immune checkpoint inhibitors,drug,39302574
chemotherapy,treatment,chemotherapy,treatment,39302574
targeted therapy,treatment,targeted therapy,treatment,39302574
corticosteroids,drug,corticosteroids,drug,39302574
immunosuppressive agents,drug,immunosuppressive agents,drug,39302574
antibody drug conjugates,drug,antibody drug conjugates,drug,39302574
computed tomography,imaging technique,computed tomography,imaging technique,39302574
ibrutinib,drug,ibrutinib,drug,39300447
lenalidomide,drug,lenalidomide,drug,39300447
primary central nervous system lymphoma,disease,primary central nervous system lymphoma,disease,39300447
methotrexate,drug,methotrexate,drug,39300447
rituximab,drug,rituximab,drug,39300447
procarbazine,drug,procarbazine,drug,39300447
vincristine,drug,vincristine,drug,39300447
prednisone,drug,prednisone,drug,39300447
aspergillosis,adverse event,aspergillosis,adverse event,39300447
pneumocystosis,adverse event,pneumocystosis,adverse event,39300447
catheter related infection,adverse event,catheter related infection,adverse event,39300447
increased alanine aminotransferase levels,adverse event,increased alanine aminotransferase levels,adverse event,39300447
hepatic cytolysis,adverse event,hepatic cytolysis,adverse event,39300447
neutropenia,adverse event,neutropenia,adverse event,39300447
infections,adverse event,infections,adverse event,39300447
Lyell's syndrome,adverse event,Lyell's syndrome,adverse event,39300447
5 fluorouracil,drug,5 fluorouracil,drug,39300121
colorectal cancer malignancy,disease,colorectal cancer malignancy,disease,39300121
senescent cells,cellular component,senescent cells,cellular component,39300121
oleanolic acid,drug,oleanolic acid,drug,39300121
human umbilical vein endothelial cells,cell line,human umbilical vein endothelial cells,cell line,39300121
human normal intestinal epithelial cells,cell line,human normal intestinal epithelial cells,cell line,39300121
senescence associated proteins,protein,senescence associated proteins,protein,39300121
senescence associated genes,gene,senescence associated genes,gene,39300121
senescence associated secretory phenotypes,cellular component,senescence associated secretory phenotypes,cellular component,39300121
IL-1,protein,IL-1,protein,39300121
IL-6,protein,IL-6,protein,39300121
IL-8,protein,IL-8,protein,39300121
IFN,protein,IFN,protein,39300121
TNF,protein,TNF,protein,39300121
mTOR,protein,mTOR,protein,39300121
HCT116 cells,cell line,HCT116 cells,cell line,39300121
SW480 cells,cell line,SW480 cells,cell line,39300121
Balb/c mouse model,animal model,Balb/c mouse model,animal model,39300121
Gemox,drug,Gemox,drug,39299973
Gemcitabine,drug,Gemcitabine,drug,39299973
Oxaliplatin,drug,Oxaliplatin,drug,39299973
Sintilimab,drug,Sintilimab,drug,39299973
Immune checkpoint inhibitors,class_id,Immune checkpoint inhibitors,class_id,39299973
PD-1 receptor,class_id,PD-1 receptor,class_id,39299973
Nodal PTCLs,class_id,Nodal PTCLs,class_id,39299973
Salvage therapy,class_id,Salvage therapy,class_id,39299973
Autologous stem cell transplantation,class_id,Autologous stem cell transplantation,class_id,39299973
Histone deacetylase inhibitors,class_id,Histone deacetylase inhibitors,class_id,39299973
Adverse event,class_id,Adverse event,class_id,39299973
neurologic immune related adverse events,semantic_types,neurologic immune related adverse events,semantic_types,39298719
immune checkpoint inhibitors,semantic_types,immune checkpoint inhibitors,semantic_types,39298719
Italian hospitals,semantic_types,Italian hospitals,semantic_types,39298719
peripheral nervous system,semantic_types,peripheral nervous system,semantic_types,39298719
central nervous system,semantic_types,central nervous system,semantic_types,39298719
myocarditis,semantic_types,myocarditis,semantic_types,39298719
cerebellar ataxia,semantic_types,cerebellar ataxia,semantic_types,39298719
neuromuscular weakness,semantic_types,neuromuscular weakness,semantic_types,39298719
visual loss,semantic_types,visual loss,semantic_types,39298719
sensory disturbances,semantic_types,sensory disturbances,semantic_types,39298719
focal neurologic signs,semantic_types,focal neurologic signs,semantic_types,39298719
cognitive impairment,semantic_types,cognitive impairment,semantic_types,39298719
severe neurologic disability,semantic_types,severe neurologic disability,semantic_types,39298719
cancer progression,semantic_types,cancer progression,semantic_types,39298719
nsclc,preferred_label,nsclc,preferred_label,39298516
rhodium,preferred_label,rhodium,preferred_label,39298516
2-benzoylpyridine thiosemicarbazone complexes,preferred_label,2-benzoylpyridine thiosemicarbazone complexes,preferred_label,39298516
rh4,preferred_label,rh4,preferred_label,39298516
aft nanoparticle,preferred_label,aft nanoparticle,preferred_label,39298516
multidrug resistant nsclc,preferred_label,multidrug resistant nsclc,preferred_label,39298516
immune and metabolic tumor microenvironments,preferred_label,immune and metabolic tumor microenvironments,preferred_label,39298516
breast cancer,class_id,breast cancer,class_id,39294665
chemotherapy,class_id,chemotherapy,class_id,39294665
phytomolecules,class_id,phytomolecules,class_id,39294665
combination therapy,class_id,combination therapy,class_id,39294665
drug delivery systems,class_id,drug delivery systems,class_id,39294665
novel routes of administration,class_id,novel routes of administration,class_id,39294665
phytochemicals,class_id,phytochemicals,class_id,39294665
berberine,class_id,berberine,class_id,39294665
curcumin,class_id,curcumin,class_id,39294665
quercetin,class_id,quercetin,class_id,39294665
lycopene,class_id,lycopene,class_id,39294665
sulforaphane,class_id,sulforaphane,class_id,39294665
resveratrol,class_id,resveratrol,class_id,39294665
epigallocatechin gallate,class_id,epigallocatechin gallate,class_id,39294665
apigenin,class_id,apigenin,class_id,39294665
genistein,class_id,genistein,class_id,39294665
thymoquinone,class_id,thymoquinone,class_id,39294665
polypharmacy,preferred_label,polypharmacy,preferred_label,39294452
potentially inappropriate medications (PIM),preferred_label,potentially inappropriate medications (PIM),preferred_label,39294452
older adults,preferred_label,older adults,preferred_label,39294452
advanced cancer,preferred_label,advanced cancer,preferred_label,39294452
physical functional outcomes,preferred_label,physical functional outcomes,preferred_label,39294452
medication measures,preferred_label,medication measures,preferred_label,39294452
geriatric assessment domain impairment,preferred_label,geriatric assessment domain impairment,preferred_label,39294452
antineoplastic regimen,preferred_label,antineoplastic regimen,preferred_label,39294452
polypharmacy,preferred_label,polypharmacy,preferred_label,39294452
medications (meds),preferred_label,medications (meds),preferred_label,39294452
STOPP criteria,preferred_label,STOPP criteria,preferred_label,39294452
2019 Beers criteria,preferred_label,2019 Beers criteria,preferred_label,39294452
activity of daily living (ADL),preferred_label,activity of daily living (ADL),preferred_label,39294452
instrumental ADL (IADL),preferred_label,instrumental ADL (IADL),preferred_label,39294452
short physical performance battery (SPPB),preferred_label,short physical performance battery (SPPB),preferred_label,39294452
falls,preferred_label,falls,preferred_label,39294452
multivariable cluster weighted generalized estimating equations models,preferred_label,multivariable cluster weighted generalized estimating equations models,preferred_label,39294452
relevant covariates,preferred_label,relevant covariates,preferred_label,39294452
clinicaltrials.gov identifier NCT02054741,preferred_label,clinicaltrials.gov identifier NCT02054741,preferred_label,39294452
lutetium 177,preferred_label,lutetium 177,preferred_label,39293461
prostate specific membrane antigen,preferred_label,prostate specific membrane antigen,preferred_label,39293461
metastatic castration resistant prostate cancer,preferred_label,metastatic castration resistant prostate cancer,preferred_label,39293461
docetaxel,preferred_label,docetaxel,preferred_label,39293461
high volume metastatic hormone sensitive prostate cancer,preferred_label,high volume metastatic hormone sensitive prostate cancer,preferred_label,39293461
177lu lu psma 617,preferred_label,177lu lu psma 617,preferred_label,39293461
de novo high volume metastatic hormone sensitive prostate cancer,preferred_label,de novo high volume metastatic hormone sensitive prostate cancer,preferred_label,39293461
Chemoradiotherapy,preferred_label,Chemoradiotherapy,preferred_label,39287161
Platinum Etoposide Chemotherapy,preferred_label,Platinum Etoposide Chemotherapy,preferred_label,39287161
Lung Cancer,preferred_label,Lung Cancer,preferred_label,39287161
Older Patients,preferred_label,Older Patients,preferred_label,39287161
Hematological Adverse Events,preferred_label,Hematological Adverse Events,preferred_label,39287161
Neutrophil Count,preferred_label,Neutrophil Count,preferred_label,39287161
tumor patients,class_id,tumor patients,class_id,39286288
cardiovascular complications,class_id,cardiovascular complications,class_id,39286288
cancer therapy related cardiovascular toxicity,class_id,cancer therapy related cardiovascular toxicity,class_id,39286288
cardiotoxicity,class_id,cardiotoxicity,class_id,39286288
anticancer drugs,class_id,anticancer drugs,class_id,39286288
heart failure,class_id,heart failure,class_id,39286288
myocarditis,class_id,myocarditis,class_id,39286288
hypertension,class_id,hypertension,class_id,39286288
arrhythmias,class_id,arrhythmias,class_id,39286288
vascular toxicity,class_id,vascular toxicity,class_id,39286288
vascular endothelial dysfunction,class_id,vascular endothelial dysfunction,class_id,39286288
ferroptosis,class_id,ferroptosis,class_id,39286288
mitochondrial dysfunction,class_id,mitochondrial dysfunction,class_id,39286288
oxidative stress,class_id,oxidative stress,class_id,39286288
therapeutic measures,class_id,therapeutic measures,class_id,39286288
accumulation of anticancer drugs,class_id,accumulation of anticancer drugs,class_id,39286288
cardioprotective drugs,class_id,cardioprotective drugs,class_id,39286288
mitochondrial transplantation,class_id,mitochondrial transplantation,class_id,39286288
doxorubicin,class_id,doxorubicin,class_id,39286288
metastatic breast cancer,disease,metastatic breast cancer,disease,39279590
older women (aged 65 and above),patient demographic,older women (aged 65 and above),patient demographic,39279590
genomics guided therapy,treatment approach,genomics guided therapy,treatment approach,39279590
innovative biomarkers,treatment approach,innovative biomarkers,treatment approach,39279590
systemic anticancer treatments,treatment,systemic anticancer treatments,treatment,39279590
subgroup analyses,study analysis,subgroup analyses,study analysis,39279590
real world data,data source,real world data,data source,39279590
guideline concordant,medical guideline adherence,guideline concordant,medical guideline adherence,39279590
comorbidity,medical condition,comorbidity,medical condition,39279590
social supports,support system,social supports,support system,39279590
malnutrition,medical condition,malnutrition,medical condition,39279590
geriatric factors,medical condition,geriatric factors,medical condition,39279590
frailty,medical condition,frailty,medical condition,39279590
vulnerability,medical condition,vulnerability,medical condition,39279590
multi-disciplinary team,medical team,multi-disciplinary team,medical team,39279590
immune checkpoint inhibitors,drug,immune checkpoint inhibitors,drug,39277735
immune related adverse events,adverse event,immune related adverse events,adverse event,39277735
kidney,anatomical entity,kidney,anatomical entity,39277735
anti programmed cell death protein 1 (PD-1) therapy (pembrolizumab),drug,anti programmed cell death protein 1 (PD-1) therapy (pembrolizumab),drug,39277735
renal immune related adverse events (R-IRAEs),adverse event,renal immune related adverse events (R-IRAEs),adverse event,39277735
peripheral blood mononuclear cells (PBMCs),cell type,peripheral blood mononuclear cells (PBMCs),cell type,39277735
cell clusters,cell type,cell clusters,cell type,39277735
differentially expressed genes (DEGs),molecular entity,differentially expressed genes (DEGs),molecular entity,39277735
Kyoto Encyclopedia of Genes and Genomes (KEGG),resource,Kyoto Encyclopedia of Genes and Genomes (KEGG),resource,39277735
Gene Ontology (GO),resource,Gene Ontology (GO),resource,39277735
CD4+ T cells,cell type,CD4+ T cells,cell type,39277735
CD8+ T cells,cell type,CD8+ T cells,cell type,39277735
ovarian clear cell carcinoma,class_id,ovarian clear cell carcinoma,class_id,39276785
sintilimab,preferred_label,sintilimab,preferred_label,39276785
bevacizumab,preferred_label,bevacizumab,preferred_label,39276785
patients,preferred_label,patients,preferred_label,39276785
treatment,preferred_label,treatment,preferred_label,39276785
chemotherapy,preferred_label,chemotherapy,preferred_label,39276785
phase 2 inova trial,preferred_label,phase 2 inova trial,preferred_label,39276785
adverse events,preferred_label,adverse events,preferred_label,39276785
cdk4 6 inhibitors,preferred_label,cdk4 6 inhibitors,preferred_label,39267478
endocrine therapy,preferred_label,endocrine therapy,preferred_label,39267478
hormone receptor positive advanced breast cancer,preferred_label,hormone receptor positive advanced breast cancer,preferred_label,39267478
abemaciclib,preferred_label,abemaciclib,preferred_label,39267478
palbociclib,preferred_label,palbociclib,preferred_label,39267478
ribociclib,preferred_label,ribociclib,preferred_label,39267478
dalpiciclib,preferred_label,dalpiciclib,preferred_label,39267478
progression free survival,preferred_label,progression free survival,preferred_label,39267478
lung metastasis,preferred_label,lung metastasis,preferred_label,39267478
endocrine therapy,preferred_label,endocrine therapy,preferred_label,39267478
chemotherapy,preferred_label,chemotherapy,preferred_label,39267478
hematologic toxicity,preferred_label,hematologic toxicity,preferred_label,39267478
clinical benefits,preferred_label,clinical benefits,preferred_label,39267478
safety profiles,preferred_label,safety profiles,preferred_label,39267478
patients,preferred_label,patients,preferred_label,39267478
